var title_f12_22_12640="Algorithm for CRC screening";
var content_f12_22_12640=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Algorithm for CRC screening and surveillance in average-risk and increased-risk populations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 595px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IBD: inflammatory bowel disease; CRC: colorectal cancer; FDR: first degree relative; SDR: second degree relative; CTC: computed tomographic colonography; FAP: familiar adenomatous polyposis; HNPCC: hereditary nonpolyposis colorectal cancer; DCBE: double-contrast barium enema; gFOBT: guaiac fecal occult blood test; FIT: fecal immunochemical tests; sDNA: stool DNA tests.",
"    </div>",
"    <div class=\"reference\">",
"     Recommendations reflect joint multi-society guidelines 2008. Adapted from: Winawer, SW, Fletcher, RH, Mille, L, et al, AGA guidelines: Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997; 112: 594.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_22_12640=[""].join("\n");
var outline_f12_22_12640=null;
var title_f12_22_12641="Gauze grattage of an unroofed hidradenitis suppurativa sinus";
var content_f12_22_12641=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F64990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F64990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gauze grattage of an unroofed hidradenitis suppurativa sinus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 275px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This picture shows the unroofed inflamed hidradenitis suppurativa nodule site and sinus tract. Rough gauze grattage removes the active proliferative inflammatory mass that re-populates the tract with pilosebaceous structures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: F William Danby, MD, FRCPC, FAAD. Copyright &copy; 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_22_12641=[""].join("\n");
var outline_f12_22_12641=null;
var title_f12_22_12642="Papular secondary syphilis";
var content_f12_22_12642=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Secondary syphilis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple slightly scaly erythematous papules are present on the trunk of this patient with papular secondary syphilis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_22_12642=[""].join("\n");
var outline_f12_22_12642=null;
var title_f12_22_12643="Acetabular fracture of posterior column";
var content_f12_22_12643=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66251&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66251&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Radiograph of acetabular posterior column fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 473px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) On the anteroposterior view, the displacement of the ilioischial line (arrow) is apparent while the iliopectineal line is seen to be intact (black arrowheads). As typical, the ilioischial line (arrow) is displaced relative to the radiographic U (white arrowhead).",
"    <br/>",
"    (B) The obturator oblique view confirms the anterior column to be intact (arrowheads) and demonstrates the fracture of the ischial ramus (arrow).",
"    <br/>",
"    (C) The iliac oblique view shows the disruption of the greater sciatic notch and the displacement of the posterior column (arrow).",
"    <br/>",
"    (D) The computed tomography section shows a fracture line typical of a posterior column fracture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Originally published in: Moed BR, Reilly MC. Lower extremity: Acetabulum fractures. In: Rockwood and Green's Fractures in Adults, 7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Reproduced with permission. Copyright &copy; Berton R. Moed, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_22_12643=[""].join("\n");
var outline_f12_22_12643=null;
var title_f12_22_12644="Cefaclor: Pediatric drug information";
var content_f12_22_12644=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cefaclor: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?27/11/27829?source=see_link\">",
"    see \"Cefaclor: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/31/29172?source=see_link\">",
"    see \"Cefaclor: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F146901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Cefaclor&reg;;",
"     </li>",
"     <li>",
"      Ceclor&reg;;",
"     </li>",
"     <li>",
"      Novo-Cefaclor;",
"     </li>",
"     <li>",
"      Nu-Cefaclor;",
"     </li>",
"     <li>",
"      PMS-Cefaclor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1045856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Cephalosporin (Second Generation)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1045848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/11/27829?source=see_link\">",
"      see \"Cefaclor: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants &gt;1 month and Children: 20-40 mg/kg/day divided every 8-12 hours; maximum dose: 2 g/day (twice daily option is for treatment of otitis media or pharyngitis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otitis media: 40 mg/kg/day divided every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pharyngitis: 20 mg/kg/day divided every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 250-500 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 50% of dose",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F146876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral: 125 mg/5 mL (150 mL); 250 mg/5 mL (150 mL); 375 mg/5 mL (100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F146860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1045860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Capsule, suspension: Administer 1 hour before or 2 hours after a meal; shake suspension well before use",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1045852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store capsule and unreconstituted powder for oral suspension at room temperature. Refrigerate suspension after reconstitution; discard after 14 days.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1045859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infections caused by susceptible bacteria including",
"     <i>",
"      Staph aureus",
"     </i>",
"     ,",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     ,",
"     <i>",
"      S. pyogenes",
"     </i>",
"     , and",
"     <i>",
"      H. influenzae",
"     </i>",
"     (excluding &beta;-lactamase negative, ampicillin-resistant strains); treatment of otitis media, sinusitis, and infections involving the respiratory tract, skin and skin structure, bone and joint; treatment of urinary tract infections caused by",
"     <i>",
"      E. coli",
"     </i>",
"     ,",
"     <i>",
"      Klebsiella",
"     </i>",
"     , and",
"     <i>",
"      Proteus mirabilis",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F146951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cefaclor may be confused with cephalexin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F146949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash (maculopapular, erythematous, or morbilliform)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Eosinophilia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Increased transaminases",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Moniliasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Agitation, agranulocytosis, anaphylaxis, angioedema, aplastic anemia, arthralgia, cholestatic jaundice, CNS irritability, confusion, dizziness, hallucinations, hemolytic anemia, hepatitis, hyperactivity, insomnia, interstitial nephritis, nausea, nervousness, neutropenia, paresthesia, PT prolonged, pruritus, pseudomembranous colitis, seizure, serum-sickness, somnolence, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis, urticaria, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reactions reported with other cephalosporins: Abdominal pain, cholestasis, fever, hemorrhage, renal dysfunction, superinfection, toxic nephropathy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1045863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cefaclor, any component, or cephalosporins",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1045847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with impaired renal function; adjust dose in patients with severe renal impairment. Use with caution in patients with a history  of penicillin hypersensitivity, especially IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria); cross-hypersensitivity among beta-lactam antibiotics may occur in up to 10% of patients with penicillin allergy history; may cause serum sickness-like reaction (estimated incidence ranges from 0.024% to 0.2% per drug course); majority of reactions have occurred in children &lt;5 years of age with symptoms of fever, rash, erythema multiforme, and arthralgia, often occurring during the second or third exposure.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1045846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prolonged use may result in  fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment; use with caution in patients with a history of colitis; pseudomembranous colitis reported with cefaclor.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Oral suspension contains sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse; use suspension containing sodium benzoate with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F146869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Cephalosporins (2nd Generation) may enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Cephalosporins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1045865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Capsules and suspension: Food or milk delays and decreases peak concentration",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F146872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5953385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. An increased risk of teratogenic effects has not been observed following maternal use of cefaclor.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1045855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     With prolonged therapy, monitor CBC and stool frequency periodically",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1045845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins and interfering with the final transpeptidation step of peptidoglycan synthesis resulting in cell wall death",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1045862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed; acid stable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes into tissues and fluids including bone, pleural and synovial fluid; crosses the placenta; appears in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 30-60 minutes (prolonged with renal impairment)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsule: 60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Suspension: 45-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Most of dose (80%) excreted unchanged in urine by glomerular filtration and tubular secretion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Moderately dialyzable (20% to 50%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1045854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/31/29172?source=see_link\">",
"      see \"Cefaclor: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Counsel patient that cefaclor should only be used to treat bacterial infections. Entire course of medication should be taken even if patient feels better early in the course. Report persistent diarrhea to physician.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Boguniewicz M and Leung DYM, &ldquo;Hypersensitivity Reactions to Antibiotics Commonly Used in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1995, 14(3):221-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/22/12644/abstract-text/7761188/pubmed\" id=\"7761188\" target=\"_blank\">",
"        7761188",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hyslop DL, &ldquo;Cefaclor Safety Profile: A Ten Year Review,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 1988, 11(Suppl A):83-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/22/12644/abstract-text/3242837/pubmed\" id=\"3242837\" target=\"_blank\">",
"        3242837",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine LR, &ldquo;Quantitative Comparison of Adverse Reactions to Cefaclor vs Amoxicillin in a Surveillance Study,&rdquo;",
"      <i>",
"       Pediatr Infect Dis",
"      </i>",
"      , 1985, 4(4):358-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/22/12644/abstract-text/3161007/pubmed\" id=\"3161007\" target=\"_blank\">",
"        3161007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13122 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-199.231.185.123-894C5EFDCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_22_12644=[""].join("\n");
var outline_f12_22_12644=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146901\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045856\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045848\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146876\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146860\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045860\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045852\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045859\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146951\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146949\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045863\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045847\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045846\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298983\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146869\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045865\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146872\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5953385\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045855\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045845\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045862\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045854\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13122\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13122|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/11/27829?source=related_link\">",
"      Cefaclor: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/31/29172?source=related_link\">",
"      Cefaclor: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_22_12645="Eclipse nevus 2";
var content_f12_22_12645=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F53622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F53622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eclipse nevus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A compound nevus on the scalp of a child showing a light brown center and a more intensely pigmented rim.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_22_12645=[""].join("\n");
var outline_f12_22_12645=null;
var title_f12_22_12646="Sex cord-stromal tumors of the ovary: Sertoli-stromal cell tumors";
var content_f12_22_12646=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sex cord-stromal tumors of the ovary: Sertoli-stromal cell tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/22/12646/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/22/12646/contributors\">",
"     David M Gershenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/22/12646/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/22/12646/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/22/12646/contributors\">",
"     Rochelle L Garcia, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/22/12646/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/22/12646/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/22/12646/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian sex cord-stromal tumors are a heterogeneous group of benign or malignant neoplasms that develop from the stem cells that would typically furnish cells surrounding the oocytes, including the cells that produce ovarian hormones (the nongerm cell and nonepithelial components of the gonads) (",
"    <a class=\"graphic graphic_figure graphicRef72286 \" href=\"UTD.htm?43/17/44307\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12646/abstract/1\">",
"     1",
"    </a>",
"    ]. Ovarian sex cord-stromal tumors are rare, comprising only 1.2 percent of all primary ovarian cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12646/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast with epithelial ovarian cancer, most patients with malignant sex cord-stromal tumors are diagnosed with early-stage disease; the tumors are generally considered to be low-grade malignant neoplasms.",
"   </p>",
"   <p>",
"    Sertoli-Leydig cell tumors constitute fewer than 0.5 percent of ovarian neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12646/abstract/3\">",
"     3",
"    </a>",
"    ]. They may behave in a benign or malignant fashion, which correlates with the degree of differentiation in an individual case. Approximately 75 percent occur in women under the age of 40 years (mean age at diagnosis is 25), but they occur in all age groups. The neoplasms are characterized by the presence of testicular structures that produce androgens. This can result in virilization, although not all of these neoplasms are functionally active.",
"   </p>",
"   <p>",
"    Ovarian sex cord-stromal tumors of the Sertoli-stromal cell type are reviewed here. This category includes Sertoli-Leydig cell tumors (androblastomas) as well as pure Sertoli cell or Leydig cell tumors. An overview of sex cord-stromal tumors and other types of sex cord-stromal tumors of the ovary (Sertoli-stromal cell tumors and tumors with granulosa and Sertoli-Leydig elements), as well as epithelial ovarian cancer, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16087?source=see_link\">",
"     \"Overview of sex cord-stromal tumors of the ovary\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8778?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32916?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Tumors with granulosa and Sertoli-Leydig elements\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=see_link\">",
"     \"Epithelial ovarian cancer: Pathology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Grossly, Sertoli-Leydig cell tumors typically form a firm, solid, lobulated mass with a smooth external surface [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12646/abstract/4\">",
"     4",
"    </a>",
"    ]. Well differentiated neoplasms with retiform components (ie, with papillae resembling the rete testis and rete ovarii) are often soft and spongy, while poorly differentiated subtypes may have areas of hemorrhage and necrosis. The retiform pattern has been associated with hepatocytic differentiation and elevation in serum levels of alpha-fetoprotein [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12646/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Microscopically, well differentiated neoplasms are composed of hollow or solid tubules surrounded by a fibrous stroma (",
"    <a class=\"graphic graphic_picture graphicRef65893 \" href=\"UTD.htm?32/45/33495\">",
"     picture 1",
"    </a>",
"    ). Sertoli cells line the tubules, and Leydig cells are observed within the stroma. Dense cellular areas with increasing numbers of mitoses occur in intermediate or poorly differentiated neoplasms. Five subtypes are identified: well differentiated; intermediate differentiation; poorly differentiated; retiform; and mixed. Most are histologically low-grade.",
"   </p>",
"   <p>",
"    Some Sertoli-Leydig cell tumors contain heterologous elements, or other tissue types, such as mucinous (eg, gastrointestinal) epithelium, cartilage, and skeletal muscle. The presence of nonepithelial tissues is associated with a poorer prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of these neoplasms present during the second and third decades of life. Most are unilateral, confined to the ovary, and large (average 16 cm in maximal diameter) unless discovered incidentally.",
"   </p>",
"   <p>",
"    Androgens and androgen precursors (eg, 17 hydroxyprogesterone, testosterone, androstenedione) are often produced by these tumors, resulting in virilization (oligomenorrhea, amenorrhea, breast atrophy, hirsutism, deepening voice, male pattern baldness, acne, and clitoral enlargement) in at least one-third of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12646/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Production of either inhibin or alpha-fetoprotein has also been reported in a small number of cases of Sertoli-Leydig cell tumor.",
"   </p>",
"   <p>",
"    Pure Sertoli cell tumors are usually estrogenic and may also secrete renin, leading to refractory hypertension and hypokalemia. Pure Leydig cell tumors are androgen secreting; only a few cases have been reported. Virtually all of these rare tumors are unilateral and confined to the ovary at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12646/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women without hormonal manifestations usually present with abdominal pain or increasing abdominal girth. Almost all symptomatic patients have a palpable adnexal mass.",
"   </p>",
"   <p>",
"    Despite an average size of 16 cm at presentation, only 2 to 3 percent of Sertoli-Leydig cell tumors have demonstrable extraovarian spread at the time of diagnosis; fewer than 20 percent display malignant behavior (ie, metastasize or recur) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12646/abstract/6\">",
"     6",
"    </a>",
"    ]. In contrast to granulosa cell tumors, early recurrence is typical of Sertoli-Leydig cell tumors, with only 6 to 7 percent of recurrences developing after five years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8778?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recurrences are most common with poorly differentiated tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of Sertoli-Leydig tumors is made by histology at time of surgical excision. Preoperatively, a Sertoli-Leydig tumor should be suspected based upon the presence of a large adnexal mass, if accompanied by the signs of virilization described in the preceding section.",
"   </p>",
"   <p>",
"    Serum testosterone levels are invariably elevated when virilization is present, and selective venous catheterization has documented the ovary as the site of origin [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12646/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In addition, immunostaining was positive for testosterone in eight Sertoli-Leydig tumors analyzed, including a limited number of tumors from patients without clinical signs or symptoms of androgen excess [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12646/abstract/11\">",
"     11",
"    </a>",
"    ]. The Leydig cells, as anticipated, were shown to be the cell producing testosterone. Following cytoreductive surgery, the serum testosterone levels are rapidly cleared from the circulation and have been reported on occasion to again increase as a function of the burden of recurrent metastatic disease.",
"   </p>",
"   <p>",
"    A histologic diagnosis is often made only upon final pathologic evaluation. Since these are rare tumors, many expert gynecologic pathologists will not provide a definite diagnosis based upon intraoperative frozen section examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Surgical staging and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery remains the cornerstone of treatment for patients with Sertoli-Leydig cell tumors. Sertoli-stromal cell tumors are staged surgically according to the FIGO ovarian cancer staging system (",
"    <a class=\"graphic graphic_table graphicRef55817 \" href=\"UTD.htm?24/4/24653\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Total abdominal hysterectomy with bilateral salpingo-oophorectomy and complete surgical staging is recommended for women who have completed childbearing (",
"    <a class=\"graphic graphic_table graphicRef75194 \" href=\"UTD.htm?40/8/41099\">",
"     table 2",
"    </a>",
"    ). When preservation of fertility or avoidance of exogenous hormone replacement is desired, unilateral oophorectomy can be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12646/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lymph node metastases are rare, and lymphadenectomy may be omitted during the staging procedure if the diagnosis is made on intraoperative frozen-section examination [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12646/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16087?source=see_link&amp;anchor=H727859#H727859\">",
"     \"Overview of sex cord-stromal tumors of the ovary\", section on 'Staging and surgical treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Adjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery alone is acceptable treatment for all patients with nonmetastatic disease, except for those with nonmetastatic Sertoli-Leydig cell tumors that are poorly differentiated or contain heterologous elements. Guidelines from the NCCN recommend a course of platinum-based adjuvant chemotherapy following surgery for these patients although there is no standard regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12646/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The available data evaluating the benefit of chemotherapy are scant, with most of the literature consisting of isolated case reports.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One series included three patients with stage IC Sertoli-Leydig cell tumor, two poorly differentiated [",
"      <a class=\"abstract\" href=\"UTD.htm?12/22/12646/abstract/16\">",
"       16",
"      </a>",
"      ]. Despite the early use of platinum-based chemotherapy, only one of the three (neither with a poorly differentiated tumor) was disease-free at 47 months.",
"     </li>",
"     <li>",
"      On the other hand, another report included 11 patients with Sertoli-Leydig cell ovarian tumors, five of whom received postoperative chemotherapy because of poorly differentiated histology or stage II or III disease [",
"      <a class=\"abstract\" href=\"UTD.htm?12/22/12646/abstract/17\">",
"       17",
"      </a>",
"      ]. No patient died of disease with follow-up that ranged from six months to 34 years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H535264\">",
"    <span class=\"h2\">",
"     Management of recurrent or metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overt metastatic disease is treated with chemotherapy. As with granulosa cell tumors, the optimal regimen for treatment of advanced Sertoli-Leydig cell tumors is unknown. However, BEP is recommended most often (",
"    <a class=\"graphic graphic_table graphicRef65516 \" href=\"UTD.htm?14/2/14382\">",
"     table 3",
"    </a>",
"    ). As with other advanced sex cord-stromal tumors, the rate of objective response is high, but responses are not durable.",
"   </p>",
"   <p>",
"    Other platinum-based regimens are alternatives, particularly for second-line therapy. These include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (CAP);",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ; and cisplatin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ; and",
"    <span class=\"nowrap\">",
"     taxane/platinum",
"    </span>",
"    combination therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12646/abstract/18-24\">",
"     18-24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PROGNOSIS AND FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall five year survival is 70 to 90 percent, and is related to stage and degree of histologic differentiation. In one large series of 207 patients with Sertoli-Leydig cell tumors, the level of differentiation was well, intermediate, and poor in 11, 54, and 13 percent respectively, and 22 percent contained heterologous elements [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12646/abstract/6\">",
"     6",
"    </a>",
"    ]. With prolonged follow-up, the tumor was clinically malignant (ie, it recurred",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    metastasized) in 18 percent of patients. All of the well-differentiated tumors were benign, while malignant behavior occurred in 11 percent of those with intermediate differentiation, 59 percent of poorly differentiated tumors, and 19 percent of those with heterologous elements.",
"   </p>",
"   <p>",
"    We suggest following these patients with physical examination and testosterone levels (or other markers, such as inhibin or alpha-fetoprotein, if initially elevated) (",
"    <a class=\"graphic graphic_table graphicRef55817 \" href=\"UTD.htm?24/4/24653\">",
"     table 1",
"    </a>",
"    ) every three to four months for the first two years and every six months for the subsequent three years. CT scan or other imaging is usually reserved for evaluation of symptoms or elevation in testosterone level.",
"   </p>",
"   <p>",
"    An overview of posttreatment surveillance for sex cord-stromal tumors can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16087?source=see_link&amp;anchor=H4401872#H4401872\">",
"     \"Overview of sex cord-stromal tumors of the ovary\", section on 'Posttreatment surveillance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/61/28626?source=see_link\">",
"       \"Patient information: Sertoli-Leydig cell tumor (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sertoli-Leydig cell tumors constitute fewer than 0.5 percent of ovarian tumors and may behave in a benign or malignant fashion. The neoplasms are characterized by the presence of testicular structures that produce androgens. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sertoli-stromal cell tumors often produce androgens (",
"      <a class=\"graphic graphic_table graphicRef55817 \" href=\"UTD.htm?24/4/24653\">",
"       table 1",
"      </a>",
"      ), and at least one-third of affected women present with virilization. Women without hormonal manifestations usually present with abdominal pain or increasing abdominal girth. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis of Sertoli-Leydig tumors is made by histology at time of surgical excision. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest total abdominal hysterectomy with bilateral salpingo-oophorectomy for women who have completed childbearing (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We suggest unilateral oophorectomy when preservation of fertility or avoidance of exogenous hormone replacement is desired (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Surgical staging and treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest platinum based chemotherapy rather than surgery alone for patients with stage I (",
"      <a class=\"graphic graphic_table graphicRef51205 \" href=\"UTD.htm?14/43/15038\">",
"       table 4",
"      </a>",
"      ) Sertoli-Leydig cell tumors with poor differentiation or heterologous elements (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Adjuvant therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend platinum-based chemotherapy for patients with metastatic or recurrent disease (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H535264\">",
"       'Management of recurrent or metastatic disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12646/abstract/1\">",
"      Young RH. Sex cord-stromal tumors of the ovary and testis: their similarities and differences with consideration of selected problems. Mod Pathol 2005; 18 Suppl 2:S81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12646/abstract/2\">",
"      Quirk JT, Natarajan N. Ovarian cancer incidence in the United States, 1992-1999. Gynecol Oncol 2005; 97:519.",
"     </a>",
"    </li>",
"    <li>",
"     DiSaia PJ, Creasman WT. Germ cell, stromal and other ovarian tumors. In: Clinical Gynecologic Oncology, Mosby-Yearbook, 1997. p.351.",
"    </li>",
"    <li>",
"     Young R, Clement PB, Scully RE. The ovary. In: Surgical Pathology, Sternberg SS (Ed), Raven Press, New York 1989. p.1687.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12646/abstract/5\">",
"      Mooney EE, Nogales FF, Tavassoli FA. Hepatocytic differentiation in retiform Sertoli-Leydig cell tumors: distinguishing a heterologous element from Leydig cells. Hum Pathol 1999; 30:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12646/abstract/6\">",
"      Young RH, Scully RE. Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases. Am J Surg Pathol 1985; 9:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12646/abstract/7\">",
"      Horny HP, Braumann W, Weiss E, et al. Virilizing stromal Leydig cell tumor (Leydig cell-containing thecoma) of the ovary in pregnancy. A case report with extensive immunohistochemical investigation of the tumor cells. Gen Diagn Pathol 1995; 141:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12646/abstract/8\">",
"      Oliva E, Alvarez T, Young RH. Sertoli cell tumors of the ovary: a clinicopathologic and immunohistochemical study of 54 cases. Am J Surg Pathol 2005; 29:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12646/abstract/9\">",
"      Cohen I, Shapira M, Cuperman S, et al. Direct in-vivo detection of atypical hormonal expression of a Sertoli-Leydig cell tumour following stimulation with human chorionic gonadotrophin. Clin Endocrinol (Oxf) 1993; 39:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12646/abstract/10\">",
"      Ohashi M, Hasegawa Y, Haji M, et al. Production of immunoreactive inhibin by a virilizing ovarian tumour (Sertoli-Leydig tumour). Clin Endocrinol (Oxf) 1990; 33:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12646/abstract/11\">",
"      Gagnon S, T&ecirc;tu B, Silva EG, McCaughey WT. Frequency of alpha-fetoprotein production by Sertoli-Leydig cell tumors of the ovary: an immunohistochemical study of eight cases. Mod Pathol 1989; 2:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12646/abstract/12\">",
"      Gershenson DM. Management of early ovarian cancer: germ cell and sex cord-stromal tumors. Gynecol Oncol 1994; 55:S62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12646/abstract/13\">",
"      Zhang M, Cheung MK, Shin JY, et al. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--an analysis of 376 women. Gynecol Oncol 2007; 104:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12646/abstract/14\">",
"      Brown J, Sood AK, Deavers MT, et al. Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted? Gynecol Oncol 2009; 113:86.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12646/abstract/16\">",
"      Schneider DT, Calaminus G, Wessalowski R, et al. Ovarian sex cord-stromal tumors in children and adolescents. J Clin Oncol 2003; 21:2357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12646/abstract/17\">",
"      Li B, Wu LY, Zhang WH, et al. [Clinical analysis of 11 cases of ovarian Setoli-Leydig cell tumor]. Zhonghua Fu Chan Ke Za Zhi 2004; 39:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12646/abstract/18\">",
"      Homesley HD, Bundy BN, Hurteau JA, Roth LM. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study. Gynecol Oncol 1999; 72:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12646/abstract/19\">",
"      Gershenson DM, Morris M, Burke TW, et al. Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin. Obstet Gynecol 1996; 87:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12646/abstract/20\">",
"      Gershenson DM, Copeland LJ, Kavanagh JJ, et al. Treatment of metastatic stromal tumors of the ovary with cisplatin, doxorubicin, and cyclophosphamide. Obstet Gynecol 1987; 70:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12646/abstract/21\">",
"      Tomlinson MW, Treadwell MC, Deppe G. Platinum based chemotherapy to treat recurrent Sertoli-Leydig cell ovarian carcinoma during pregnancy. Eur J Gynaecol Oncol 1997; 18:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12646/abstract/22\">",
"      Fujimoto A, Saitou M, Ishihara O, et al. [A case of ovarian malignant Sertoli-Leidig cell tumor treated with CBDCA, etoposide and epirubicin chemotherapy]. Gan To Kagaku Ryoho 1995; 22:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12646/abstract/23\">",
"      van der Meer J, de Vries EG, Vriesendorp R, et al. Hemolytic uremic syndrome in a patient on cis-platinum, vinblastine and bleomycin. J Cancer Res Clin Oncol 1985; 110:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12646/abstract/24\">",
"      Brown J, Shvartsman HS, Deavers MT, et al. The activity of taxanes in the treatment of sex cord-stromal ovarian tumors. J Clin Oncol 2004; 22:3517.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3183 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-655E7897C0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_22_12646=[""].join("\n");
var outline_f12_22_12646=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Surgical staging and treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H535264\">",
"      Management of recurrent or metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PROGNOSIS AND FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3183\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3183|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/17/44307\" title=\"figure 1\">",
"      Origins ovarian tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3183|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/45/33495\" title=\"picture 1\">",
"      Sertoli Leydig cell tumor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3183|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/4/24653\" title=\"table 1\">",
"      Ovarian tumor markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/8/41099\" title=\"table 2\">",
"      Steps in staging ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/2/14382\" title=\"table 3\">",
"      Bleomycin etoposide and cisplatin regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/43/15038\" title=\"table 4\">",
"      Staging ovarian peritoneal carcinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=related_link\">",
"      Epithelial ovarian cancer: Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16087?source=related_link\">",
"      Overview of sex cord-stromal tumors of the ovary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/61/28626?source=related_link\">",
"      Patient information: Sertoli-Leydig cell tumor (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8778?source=related_link\">",
"      Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32916?source=related_link\">",
"      Sex cord-stromal tumors of the ovary: Tumors with granulosa and Sertoli-Leydig elements",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_22_12647="Anatomy of the anal canal and rectum";
var content_f12_22_12647=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F72874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F72874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    Anatomy of the anal canal and rectum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure illustrates the anatomy of the rectum and anal canal. Note the anal crypts and glands; 90 percent of anal rectal fistulas originate in a cryptoglandular abscess. Also note the relationship of the crypts and glands to the internal and external sphincters.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_22_12647=[""].join("\n");
var outline_f12_22_12647=null;
var title_f12_22_12648="Pulmonary hypertension associated with human immunodeficiency virus";
var content_f12_22_12648=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pulmonary hypertension associated with human immunodeficiency virus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/22/12648/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/22/12648/contributors\">",
"     Michael Ieong, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/22/12648/contributors\">",
"     Harrison W Farber, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/22/12648/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/22/12648/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/22/12648/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/22/12648/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/22/12648/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human immunodeficiency virus-related pulmonary arterial hypertension (HIV-PAH) exists when pulmonary arterial hypertension (PAH) develops in a patient who has human immunodeficiency virus (HIV) infection and an alternative cause cannot be identified. More than 200 cases have been reported since its initial description in 1987 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In this topic review, the classification, prevalence, pathogenesis, clinical presentation, diagnostic evaluation, and treatment of HIV-PAH are discussed. Pulmonary hypertension that is unrelated to HIV infection is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link\">",
"     \"Overview of pulmonary hypertension in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link\">",
"     \"Treatment of pulmonary hypertension in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=see_link\">",
"     \"Clinical features and diagnosis of pulmonary hypertension in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7304?source=see_link\">",
"     \"Pathogenesis of pulmonary hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) classifies patients with pulmonary hypertension into five groups based upon etiology (",
"    <a class=\"graphic graphic_table graphicRef66348 \" href=\"UTD.htm?42/38/43628\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients in the first group are considered to have pulmonary arterial hypertension (group 1 PAH), while patients in the remaining four groups are considered to have pulmonary hypertension (group 2, group 3, group 4, and group 5 PH). When all five groups are discussed collectively, the term PH is used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of pulmonary hypertension in adults\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Human immunodeficiency virus-related pulmonary arterial hypertension (HIV-PAH) is a type of PAH. It is a member of the \"associated with PAH\" subgroup that includes diseases that have an increased prevalence of coexisting PAH (",
"    <a class=\"graphic graphic_table graphicRef66348 \" href=\"UTD.htm?42/38/43628\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/5\">",
"     5",
"    </a>",
"    ]. Also included in the subgroup is PAH associated with drugs and toxins, connective tissue diseases, portal hypertension, congenital heart disease, schistosomiasis, chronic hemolytic anemia, persistent pulmonary hypertension of the newborn, pulmonary veno-occlusive disease, and pulmonary capillary hemangiomatosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35064?source=see_link\">",
"     \"Portopulmonary hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6935?source=see_link\">",
"     \"Pulmonary vascular disease in systemic sclerosis (scleroderma): Definition, classification, risk factors, screening, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human immunodeficiency virus-related pulmonary arterial hypertension (HIV-PAH) is a rare complication of HIV infection, occurring in approximately 1 out of every 200 HIV-infected patients (0.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. This is 6- to 12-times greater than the prevalence of PAH in individuals without HIV infection.",
"   </p>",
"   <p>",
"    The largest study was a prospective cohort study of 7648 consecutive patients with HIV, which found a prevalence of HIV-PAH of 0.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/8\">",
"     8",
"    </a>",
"    ]. The study was performed during the era of antiretroviral therapy, suggesting that antiretroviral therapy has not altered the prevalence of HIV-PAH.",
"   </p>",
"   <p>",
"    Such studies likely underestimate the true prevalence of HIV-PAH because the disease often exists prior to the onset of symptoms and diagnosis. Asymptomatic disease is not included in the prevalence estimate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of human immunodeficiency virus-related pulmonary arterial hypertension (HIV-PAH) is uncertain. Both viral and host factors likely play important roles, although the relative contributions of each are difficult to discern because many patients with HIV infection have coexisting conditions that are independently associated with PAH (eg, intravenous drug use, hepatitis B or C infection) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/2,9\">",
"     2,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plexiform lesions are the hallmark histopathologic finding in patients with severe PAH, including HIV-PAH. They are characterized by abnormal endothelial cells, intimal disruption, medial hypertrophy, thrombosis, and lumenal obliteration with recanalization [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. HIV infection probably does not directly cause the plexiform lesions since HIV is not known to infect endothelial cells. However, HIV infection may affect the same pathways that produce plexiform lesions in other types of PAH. Supporting this theory, the plexiform lesions of HIV-PAH are indistinguishable from those seen in patients who have idiopathic PAH (IPAH) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     HIV-related factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV proteins may contribute to the development of HIV-PAH, as suggested by the following data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      gp120 &ndash; gp120 is an HIV surface glycoprotein that facilitates the binding of HIV to CD4-positive T lymphocytes. It stimulates in vitro secretion of endothelin-1, a molecule known to contribute to IPAH by inducing vasoconstriction and smooth muscle proliferation [",
"      <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/14\">",
"       14",
"      </a>",
"      ]. Endothelin-1 may similarly contribute to HIV-PAH, a theory supported by the observation that circulating monocytes from patients with HIV infection have increased endothelin-1 gene expression.",
"     </li>",
"     <li>",
"      Tat &ndash; Tat is an HIV transactivator that is indispensable for viral replication. Tat downregulates the expression of bone morphogenetic protein receptor type II (BMPR2), a molecule whose usual function is to induce apoptosis in a variety of cell types [",
"      <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/15\">",
"       15",
"      </a>",
"      ]. Insufficient BMPR2 function permits excess endothelial cell growth and proliferation in response to injury, which may contribute to PAH [",
"      <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7304?source=see_link&amp;anchor=H5#H5\">",
"       \"Pathogenesis of pulmonary hypertension\", section on 'Genetic mutations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nef &ndash; Nef is an HIV adaptor protein that is critical for the maintenance of high levels of HIV RNA. Nef exists in the alveolar mononuclear cells and endothelial cells of patients who have HIV-PAH [",
"      <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/10\">",
"       10",
"      </a>",
"      ]. In animals, infection with a Nef-positive virus induces plexiform lesions, whereas infection with a Nef-negative virus does not. These data imply that Nef may contribute to formation of plexiform lesions in patients with HIV-PAH.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other viral factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human herpes virus 8 (HHV-8) is a common coinfection in patients with HIV infection. It is the causative agent of Kaposi's sarcoma (whose endothelial abnormalities closely resemble the plexiform lesions characteristic of PAH) and primary effusion lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/18\">",
"     18",
"    </a>",
"    ]. Whether HHV-8 has a role in the development of HIV-PAH has not been evaluated, although the preponderance of evidence suggests that it probably does not cause IPAH [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7304?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathogenesis of pulmonary hypertension\", section on 'Herpesvirus-8'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Host factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals who have a specific human leukocyte antigen (HLA) may be predisposed to HIV-PAH. In a case-control study, the frequency of HLA class II DR52 and DR6 was increased among patients with HIV-PAH, compared to both healthy subjects and a racially diverse group of patients with HIV infection who did not have PAH [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Numerous host cytokines are increased in patients with HIV infection and have effects that may contribute to the development of HIV-PAH. Examples include interleukin (IL)-6, tumor necrosis factor-alpha, IL-1 beta, and platelet-derived growth factor (PDGF), which can induce a procoagulant state, increase the expression of endothelial adhesion molecules, and increase the accumulation of inflammatory cells in the pulmonary arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. However, these cytokines are unlikely to be the sole cause of HIV-PAH because they are elevated in all patients with HIV infection, only a fraction of whom develop HIV-PAH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients have known human immunodeficiency virus (HIV) infection and present with new symptoms and signs related to pulmonary arterial hypertension (PAH) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/2\">",
"     2",
"    </a>",
"    ]. The symptoms and signs associated with human immunodeficiency virus-related pulmonary arterial hypertension (HIV-PAH) are similar to those associated with other types of PAH [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/2,26\">",
"     2,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of pulmonary hypertension in adults\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The average duration from the detection of HIV infection until the onset of PAH-related symptoms is 27 months. The CD4-positive T lymphocyte may be low or normal; it does not correlate with the likelihood that HIV-PAH exists or its hemodynamic severity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of human immunodeficiency virus-related pulmonary arterial hypertension (HIV-PAH) requires confirmation of PAH, confirmation of HIV infection, and exclusion of alternative causes of pulmonary hypertension (PH).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Confirm PAH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Right heart catheterization is necessary to confirm PAH, which occurs when the following criteria are met [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mean pulmonary artery pressure (mPAP) &ge;25 mmHg at rest",
"     </li>",
"     <li>",
"      Pulmonary capillary wedge pressure (PCWP) &le;15 mmHg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Supportive data include an elevated pulmonary vascular resistance and transpulmonary gradient. The transpulmonary gradient is defined as the difference between the mean pulmonary arterial pressure and the pulmonary capillary wedge pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Confirm HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV infection is usually confirmed by detecting antibodies to the virus. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link\">",
"     \"Diagnostic assays for HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Exclude alternatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Group 2, 3, 4, and 5 PH must be excluded before a patient who has both PAH and HIV infection can be diagnosed with HIV-PAH (",
"    <a class=\"graphic graphic_table graphicRef66348 \" href=\"UTD.htm?42/38/43628\">",
"     table 1",
"    </a>",
"    ). This requires additional diagnostic testing, such as echocardiography, chest radiography or computed tomography, pulmonary function testing, polysomnography, ventilation-perfusion scanning or pulmonary angiography, autoantibody testing, or spirometry. Testing should be prioritized according to which alternative etiologies seem most likely. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=see_link\">",
"     \"Clinical features and diagnosis of pulmonary hypertension in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of pulmonary hypertension in adults\", section on 'Etiologies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, alternative types of group 1 PAH do not need to be excluded and frequently coexist. A systematic review of 131 published cases of presumed HIV-PAH found that 18 percent of patients had another condition associated with PAH, usually intravenous drug use, hepatitis B infection, or hepatitis C infection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality appears to be high among patients with human immunodeficiency virus-related pulmonary arterial hypertension (HIV-PAH). However, the data needs to be interpreted with caution because the management of patients was not uniform among or within studies, plus many of the studies included patients who were managed before highly active antiretroviral therapy (HAART) became common:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The systematic review of 131 patients with HIV-PAH described above found that 50 percent of the patients died during a median follow-up of eight months [",
"      <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/2\">",
"       2",
"      </a>",
"      ]. Among the patients who died, 64 percent of the deaths were a consequence of PAH. The median duration from the diagnosis of HIV-PAH until death was six months. Few patients were reported to have received antiretroviral or advanced therapy for PAH.",
"     </li>",
"     <li>",
"      An observational study of 35 patients with HIV-PAH found that 23 patients died (66 percent), with a median survival duration of 2.7 years after diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/26\">",
"       26",
"      </a>",
"      ]. Most of the deaths were attributable to HIV infection (52 percent), with fewer due to PAH (32 percent) or undetermined (16 percent). Approximately two-thirds of patients received antiretroviral therapy, but few received advanced therapy for PAH.",
"     </li>",
"     <li>",
"      An observational study of 82 patients with HIV-PAH demonstrated a one-, two-, and three-year mortality rate of 27, 40, and 53 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/28\">",
"       28",
"      </a>",
"      ]. Approximately one-half of patients received antiretroviral therapy and one-fourth received advanced therapy for PAH.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A more recent series of 77 patients with HIV-PAH in the modern therapeutic era, suggests that mortality has improved [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/29\">",
"     29",
"    </a>",
"    ]. The one- and three-year survival rates were 88 and 72 percent, respectively, which is better than historical controls. All of the patients in the series received HAART and 50 patients (65 percent) received advanced therapy for their PAH.",
"   </p>",
"   <p>",
"    A low CD4-positive T lymphocyte count may be associated with mortality due to HIV-PAH [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of pulmonary arterial hypertension (PAH) can be divided conceptually into primary therapy and advanced therapy. Primary therapy targets factors contributing to the PAH and sequelae of the PAH, while advanced therapy refers to the administration of agents with complex mechanisms of action including vasodilation and inhibition of vascular growth. Primary and advanced therapy for human immunodeficiency virus-related pulmonary arterial hypertension (HIV-PAH) are virtually identical to that for other types of PAH, which are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link\">",
"     \"Treatment of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Only aspects of treatment that are unique to HIV-PAH are discussed in this section. These include antiretroviral therapy and calcium channel blocker therapy. Clinical outcome data from trials of advanced therapy for HIV-PAH are also described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Antiretroviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;HAART is effective at suppressing HIV replication and restoring immune function in patients who are treatment candidates. However, its initiation for the sole purpose of treating HIV-PAH is not indicated due to conflicting data regarding its effectiveness.",
"   </p>",
"   <p>",
"    In one retrospective cohort study of 35 patients with HIV-PAH, outcomes were compared among patients who received combination antiretroviral therapy (n = 14), a single nucleoside analog reverse-transcriptase inhibitor (n = 12), or no antiretroviral therapy (n = 9) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/26\">",
"     26",
"    </a>",
"    ]. Only patients treated with combination antiretroviral therapy had hemodynamic improvement, as measured by Doppler echocardiography. In addition, there appeared to be fewer deaths attributable to PAH among patients who received combination antiretroviral therapy. These results should be considered with caution because the patients who received combination antiretroviral therapy were managed during different therapeutic eras and were more likely to receive PAH-directed therapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In contrast, a cohort study of 82 patients with HIV-PAH found that survival worsened when patients were begun on HAART in the absence of advanced therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium channel blockers are not used for the treatment of HIV-PAH because efficacy has not been documented and intolerable side effects can develop [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/30\">",
"     30",
"    </a>",
"    ]. These include significant hypotension due to systemic vasodilation and decreased right ventricular filling.",
"   </p>",
"   <p>",
"    Patients with HIV-PAH do not need to undergo routine vasoreactivity testing because calcium channel blocker therapy is not administered, regardless of the outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of pulmonary hypertension in adults\", section on 'Vasoreactivity test'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Advanced therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small clinical trials of advanced therapy have been performed in patients with HIV-PAH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Epoprostenol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both intravenous and inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    improve hemodynamics and symptoms in patients with HIV-PAH [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/28,31-34\">",
"     28,31-34",
"    </a>",
"    ]. This was illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"       epoprostenol",
"      </a>",
"      was evaluated in an uncontrolled clinical trial of six patients with HIV-PAH [",
"      <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/33\">",
"       33",
"      </a>",
"      ]. Acute infusion of epoprostenol decreased the mean pulmonary artery pressure (mean 8.5 mmHg) and pulmonary vascular resistance (mean 216",
"      <span class=\"nowrap\">",
"       dyn/sec",
"      </span>",
"      per cm-5), while increasing the cardiac output (mean 2",
"      <span class=\"nowrap\">",
"       L/min)",
"      </span>",
"      and cardiac index (mean 1.1",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      per m",
"      <sup>",
"       2",
"      </sup>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/33\">",
"       33",
"      </a>",
"      ]. Repeat catheterization of five patients after one year of intravenous epoprostenol therapy demonstrated further improvement in hemodynamics (",
"      <a class=\"graphic graphic_figure graphicRef64309 \" href=\"UTD.htm?37/46/38638\">",
"       figure 1",
"      </a>",
"      ). Ongoing hemodynamic benefit was observed after two years in three patients and after four years in two patients. In addition, the New York Heart Association (NYHA) functional class improved in all of the patients (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 2",
"      </a>",
"      ). The frequency of adverse effects and complications were similar in these patients, compared to that reported in patients with IPAH.",
"     </li>",
"     <li>",
"      Inhaled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"       epoprostenol",
"      </a>",
"      was evaluated in two patients with HIV-PAH [",
"      <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/32\">",
"       32",
"      </a>",
"      ]. Seven months of inhaled epoprostenol therapy was associated with improved walking distance, NYHA functional class, mean pulmonary artery pressure (mPAP), and pulmonary vascular resistance (PVR).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"     Epoprostenol",
"    </a>",
"    may also improve PAH-related mortality. Although five of the six patients in the uncontrolled clinical trial described above died, none of the deaths were due to PAH [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/32\">",
"     32",
"    </a>",
"    ]. The surviving patient has been treated with epoprostenol for more than 15 years with continued hemodynamic benefit. The administration of epoprostenol is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link&amp;anchor=H22#H22\">",
"     \"Treatment of pulmonary hypertension in adults\", section on 'Epoprostenol'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Treprostinil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/52/25414?source=see_link\">",
"     Treprostinil",
"    </a>",
"    can be administered subcutaneously or intravenously, although subcutaneous administration is less commonly prescribed due to severe pain at the injection site. Treprostinil may improve the symptoms and hemodynamics of patients with HIV-PAH.",
"   </p>",
"   <p>",
"    This was demonstrated by an uncontrolled clinical trial in which three patients with HIV-PAH were treated with subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/52/25414?source=see_link\">",
"     treprostinil",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/35\">",
"     35",
"    </a>",
"    ]. The six-minute walk distance and NYHA functional class (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    ) improved at one year in all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/35\">",
"     35",
"    </a>",
"    ]. In addition, the systolic pulmonary artery pressure (estimated by echocardiography) improved in two of the patients. No serious adverse events were observed. The use of treprostinil to treat PAH is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link&amp;anchor=H23#H23\">",
"     \"Treatment of pulmonary hypertension in adults\", section on 'Treprostinil'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Iloprost",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"     Iloprost",
"    </a>",
"    is an inhaled prostanoid that may also improve the symptoms and hemodynamics of patients with HIV-PAH. In an uncontrolled clinical trial, eight patients with HIV-PAH were treated with inhaled iloprost [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/36\">",
"     36",
"    </a>",
"    ]. There was acute improvement of the PVR and cardiac index. Among the four patients who continued with long-term iloprost, the six-minute walking distance increased and the hemodynamic improvement persisted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Bosentan",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"     Bosentan",
"    </a>",
"    is an oral nonselective endothelin receptor antagonist that blocks endothelin-1, a vasoconstrictor and smooth muscle mitogen. Bosentan appears to improve the symptoms and hemodynamics of patients with HIV-PAH.",
"   </p>",
"   <p>",
"    This was illustrated by an uncontrolled clinical trial in which 16 patients with HIV-PAH received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"     bosentan",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/37\">",
"     37",
"    </a>",
"    ]. Their six-minute walk distance, NYHA functional class (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    ), hemodynamics (mPAP, PVR, cardiac index), Doppler echocardiographic variables (right ventricle size and function), and quality of life all improved at 16 weeks. Bosentan did not have an adverse impact on the control of HIV infection.",
"   </p>",
"   <p>",
"    These observations were supported by a subsequent retrospective cohort study that evaluated the effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"     bosentan",
"    </a>",
"    in patients with HIV-PAH over a longer duration. The study enrolled 59 patients, among whom 56 were evaluated after four months of therapy and 38 were evaluated over a mean of 29 months [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/38\">",
"     38",
"    </a>",
"    ]. Survival at 1, 2, and 3 years was 93, 86, and 66 percent, respectively. The improvements in the six-minute walk distance, PVR, and NYHA functional class persisted for at least 2.5 years. This study included 12 of the 16 patients who were in the uncontrolled clinical trial described above.",
"   </p>",
"   <p>",
"    The selective endothelin receptor antagonist,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/60/29637?source=see_link\">",
"     ambrisentan",
"    </a>",
"    , has not been studied in patients with HIV-PAH.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"     Bosentan",
"    </a>",
"    is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link&amp;anchor=H26#H26\">",
"     \"Treatment of pulmonary hypertension in adults\", section on 'Bosentan'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Sildenafil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     Sildenafil",
"    </a>",
"    is a cyclic GMP phosphodiesterase type 5 (PDE5) inhibitor. It slows the degradation of cGMP, prolonging the vasodilatory effect of nitric oxide.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     Sildenafil",
"    </a>",
"    appears to improve symptoms and hemodynamics in patients with HIV-PAH, according to case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. However, careful consideration of potential interactions with concurrent anti-retroviral medications is necessary, since protease inhibitors can cause a significant increase in the levels of sildenafil and sildenafil may significantly decrease levels of protease inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12648/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No adverse events attributable to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    have been reported. Alternative PDE5 inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    ) have not been studied in patients with HIV-PAH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Human immunodeficiency virus-related pulmonary arterial hypertension (HIV-PAH) refers to pulmonary arterial hypertension (PAH) that develops in a patient who has human immunodeficiency virus (HIV) infection. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"     <li>",
"      HIV-PAH is a rare complication of HIV infection, although studies likely underestimate its true prevalence. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"     <li>",
"      The cause of HIV-PAH is uncertain. Both viral and host factors likely play important roles, although the relative contributions of each are difficult to discern because many patients with HIV infection have coexisting conditions that are independently associated with PAH. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"     <li>",
"      Most patients with HIV-PAH have known HIV infection and present with new symptoms related to PAH. The diagnosis should be considered in any HIV-infected patient who complains of dyspnea. HIV infection is occasionally identified after the detection of PAH. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"     <li>",
"      Diagnosis of HIV-PAH requires confirmation of PAH by right heart catheterization, confirmation of HIV infection by serologic testing, and exclusion of group 2, 3, 4, and 5 PH (",
"      <a class=\"graphic graphic_table graphicRef66348 \" href=\"UTD.htm?42/38/43628\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"     <li>",
"      The&nbsp;outcome of HIV-PAH has improved and is now similar to that of patients with idiopathic PAH. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Natural history'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"     <li>",
"      Primary and advanced therapies for HIV-PAH are nearly identical to that for other types of PAH, which are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link\">",
"       \"Treatment of pulmonary hypertension in adults\"",
"      </a>",
"      .) Aspects of treatment that are unique to patients with HIV-PAH include:",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest that antiretroviral therapy NOT be initiated for the sole purpose of improving HIV-PAH (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Antiretroviral therapy may be indicated for treatment of HIV infection, but this is discussed separately. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Antiretroviral therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"       \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest that calcium channel blockers NOT be administered as advanced therapy in patients with HIV-PAH (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/1\">",
"      Kim KK, Factor SM. Membranoproliferative glomerulonephritis and plexogenic pulmonary arteriopathy in a homosexual man with acquired immunodeficiency syndrome. Hum Pathol 1987; 18:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/2\">",
"      Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-Related pulmonary hypertension: analytic review of 131 cases. Chest 2000; 118:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/3\">",
"      Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/4\">",
"      Petrosillo N, Chinello P, Cicalini S. Pulmonary hypertension in individuals with HIV infection. AIDS 2006; 20:2128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/5\">",
"      Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/6\">",
"      Speich R, Jenni R, Opravil M, et al. Primary pulmonary hypertension in HIV infection. Chest 1991; 100:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/7\">",
"      Barbarinia G, Barbaro G. Incidence of the involvement of the cardiovascular system in HIV infection. AIDS 2003; 17 Suppl 1:S46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/8\">",
"      Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008; 177:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/9\">",
"      Burkart KM, Farber HW. HIV-associated pulmonary hypertension: diagnosis and treatment. Adv Cardiol 2003; 40:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/10\">",
"      Marecki JC, Cool CD, Parr JE, et al. HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques. Am J Respir Crit Care Med 2006; 174:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/11\">",
"      Wang Y, Luo Y, Yuan Y, et al. [Measurement and clinical significance of inspiratory drive efficacy in patients with chronic obstructive pulmonary disease]. Hua Xi Yi Ke Da Xue Xue Bao 1997; 28:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/12\">",
"      Mette SA, Palevsky HI, Pietra GG, et al. Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am Rev Respir Dis 1992; 145:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/13\">",
"      Humbert M, Monti G, Fartoukh M, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998; 11:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/14\">",
"      Ehrenreich H, Rieckmann P, Sinowatz F, et al. Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. J Immunol 1993; 150:4601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/15\">",
"      Caldwell RL, Gadipatti R, Lane KB, Shepherd VL. HIV-1 TAT represses transcription of the bone morphogenic protein receptor-2 in U937 monocytic cells. J Leukoc Biol 2006; 79:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/16\">",
"      Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/17\">",
"      Kimura N, Matsuo R, Shibuya H, et al. BMP2-induced apoptosis is mediated by activation of the TAK1-p38 kinase pathway that is negatively regulated by Smad6. J Biol Chem 2000; 275:17647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/18\">",
"      Weiss RA, Whitby D, Talbot S, et al. Human herpesvirus type 8 and Kaposi's sarcoma. J Natl Cancer Inst Monogr 1998; :51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/19\">",
"      Cool CD, Rai PR, Yeager ME, et al. Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med 2003; 349:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/20\">",
"      Henke-Gendo C, Mengel M, Hoeper MM, et al. Absence of Kaposi's sarcoma-associated herpesvirus in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2005; 172:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/21\">",
"      Katano H, Hogaboam CM. Herpesvirus-associated pulmonary hypertension? Am J Respir Crit Care Med 2005; 172:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/22\">",
"      Montani D, Marcelin AG, Sitbon O, et al. Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France. AIDS 2005; 19:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/23\">",
"      Morse JH, Barst RJ, Itescu S, et al. Primary pulmonary hypertension in HIV infection: an outcome determined by particular HLA class II alleles. Am J Respir Crit Care Med 1996; 153:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/24\">",
"      Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 151:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/25\">",
"      Pellicelli AM, Palmieri F, Cicalini S, Petrosillo N. Pathogenesis of HIV-related pulmonary hypertension. Ann N Y Acad Sci 2001; 946:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/26\">",
"      Zuber JP, Calmy A, Evison JM, et al. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis 2004; 38:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/27\">",
"      Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54:S55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/28\">",
"      Nunes H, Humbert M, Sitbon O, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003; 167:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/29\">",
"      Degano B, Guillaume M, Savale L, et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS 2010; 24:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/30\">",
"      Opravil M, Pech&egrave;re M, Speich R, et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 1997; 155:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/31\">",
"      Petitpretz P, Brenot F, Azarian R, et al. Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. Circulation 1994; 89:2722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/32\">",
"      Stricker H, Domenighetti G, Mombelli G. Prostacyclin for HIV-associated pulmonary hypertension. Ann Intern Med 1997; 127:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/33\">",
"      Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 2000; 162:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/34\">",
"      Farber HW. HIV-associated pulmonary hypertension. AIDS Clin Care 2001; 13:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/35\">",
"      Cea-Calvo L, Escribano Sub&iacute;as P, Tello de Menesses R, et al. [Treatment of HIV-associated pulmonary hypertension with treprostinil]. Rev Esp Cardiol 2003; 56:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/36\">",
"      Ghofrani HA, Friese G, Discher T, et al. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. Eur Respir J 2004; 23:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/37\">",
"      Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 170:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/38\">",
"      Degano B, Ya&iuml;ci A, Le Pavec J, et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J 2009; 33:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/39\">",
"      Carlsen J, Kjeldsen K, Gerstoft J. Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension. AIDS 2002; 16:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/40\">",
"      Schumacher YO, Zdebik A, Huonker M, Kreisel W. Sildenafil in HIV-related pulmonary hypertension. AIDS 2001; 15:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/41\">",
"      Wong AR, Rasool AH, Abidin NZ, et al. Sildenafil as treatment for Human Immunodeficiency Virus-related pulmonary hypertension in a child. J Paediatr Child Health 2006; 42:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12648/abstract/42\">",
"      Romanazzi S, Manes A, Hirani N, et al.. Sildenafil therapy for patients with pulmonary arterial hypertension associated with HIV infection. Am J Respir Crit Care Med 2007; :A1001.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8246 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-593C6D74E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_22_12648=[""].join("\n");
var outline_f12_22_12648=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HIV-related factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other viral factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Host factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Confirm PAH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Confirm HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Exclude alternatives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Advanced therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Epoprostenol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Treprostinil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Iloprost",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Bosentan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Sildenafil",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/8246\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8246|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/46/38638\" title=\"figure 1\">",
"      Epoprostenol in HIV PAH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8246|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/38/43628\" title=\"table 1\">",
"      WHO pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 2\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=related_link\">",
"      Clinical features and diagnosis of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=related_link\">",
"      Diagnostic assays for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7304?source=related_link\">",
"      Pathogenesis of pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35064?source=related_link\">",
"      Portopulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6935?source=related_link\">",
"      Pulmonary vascular disease in systemic sclerosis (scleroderma): Definition, classification, risk factors, screening, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=related_link\">",
"      Treatment of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_22_12649="Ethinyl estradiol and ethynodiol diacetate: Drug information";
var content_f12_22_12649=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ethinyl estradiol and ethynodiol diacetate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/2/11302?source=see_link\">",
"    see \"Ethinyl estradiol and ethynodiol diacetate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F168266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Kelnor&trade;;",
"     </li>",
"     <li>",
"      Zovia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F168267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Demulen&reg; 30",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F168286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Contraceptive;",
"     </li>",
"     <li>",
"      Estrogen and Progestin Combination",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F168270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Females: Contraception: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Schedule 1 (Sunday starter): Dose begins on first Sunday after onset of menstruation; if the menstrual period starts on Sunday, take first tablet that very same day.",
"     <b>",
"      With a Sunday start, an additional method of contraception should be used until after the first 7 days of consecutive administration:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     For 21-tablet package: 1 tablet/day for 21 consecutive days, followed by 7 days off of the medication; a new course begins on the 8th day after the last tablet is taken",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     For 28-tablet package: 1 tablet/day without interruption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Schedule 2 (Day-1 starter): Dose starts on first day of menstrual cycle taking 1 tablet/day:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     For 21-tablet package: 1 tablet/day for 21 consecutive days, followed by 7 days off of the medication; a new course begins on the 8th day after the last tablet is taken",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     For 28-tablet package: 1 tablet/day without interruption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If all doses have been taken on schedule and one menstrual period is missed, continue dosing cycle. If two consecutive menstrual periods are missed, pregnancy test is required before new dosing cycle is started.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Missed doses",
"     <b>",
"      monophasic formulations",
"     </b>",
"     (refer to package insert for complete information):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     One dose missed: Take as soon as remembered or take 2 tablets next day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Two consecutive doses missed in the first 2 weeks: Take 2 tablets as soon as remembered or 2 tablets next 2 days.",
"     <b>",
"      An additional method of contraception should be used for 7 days after missed dose.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Two consecutive doses missed in week 3 or three consecutive doses missed at any time:",
"     <b>",
"      An additional method of contraception must be used for 7 days after a missed dose:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Schedule 1 (Sunday starter): Continue dose of 1 tablet daily until Sunday, then discard the rest of the pack, and a new pack should be started that same day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Schedule 2 (Day-1 starter): Current pack should be discarded, and a new pack should be started that same day.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F168280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Females: Contraception: Oral: Refer to adult dosing; not to be used prior to menarche.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F168271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Specific guidelines not available; use with caution and monitor blood pressure closely. Consider other forms of contraception.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F168272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contraindicated in patients with hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F168247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [monophasic formulation]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kelnor&trade; 1/35: Ethinyl estradiol 0.035 mg and ethynodiol diacetate 1 mg [21 light yellow tablets and 7 white inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zovia&reg; 1/35-28: Ethinyl estradiol 0.035 mg and ethynodiol diacetate 1 mg [21 light pink tablets and 7 white inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zovia&reg; 1/50-28: Ethinyl estradiol 0.05 mg and ethynodiol diacetate 1 mg [21 pink tablets and 7 white inactive tablets] (28s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F168232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F168249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer at the same time each day. Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F168248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F168283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypermenorrhea (menorrhagia); pain associated with endometriosis; dysmenorrhea; dysfunctional uterine bleeding",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F168293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Demulen&reg; may be confused with Dalmane&reg;, Demerol&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F168284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arterial thromboembolism, cerebral hemorrhage, cerebral thrombosis, edema, hypertension, mesenteric thrombosis, MI",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Depression, dizziness, headache, migraine, nervousness, premenstrual syndrome, stroke",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, erythema multiforme, erythema nodosum, hirsutism, loss of scalp hair, melasma (may persist), rash (allergic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, breakthrough bleeding, breast enlargement, breast secretion, breast tenderness, carbohydrate intolerance, lactation decreased (postpartum), glucose tolerance decreased, libido changes, menstrual flow changes, sex hormone-binding globulins (SHBG) increased, spotting, temporary infertility (following discontinuation), thyroid-binding globulin increased, triglycerides increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, appetite changes, bloating, cholestasis, colitis, gallbladder disease, jaundice, nausea, vomiting, weight gain/loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Cervical erosion changes, cervical secretion changes, cystitis-like syndrome, vaginal candidiasis, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Antithrombin III decreased, folate levels decreased, hemolytic uremic syndrome, norepinephrine induced platelet aggregability increased, porphyria, prothrombin increased; factors VII, VIII, IX, and X increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Benign liver tumors, Budd-Chiari syndrome, cholestatic jaundice, hepatic adenomas",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Cataracts, change in corneal curvature (steepening), contact lens intolerance, optic neuritis, retinal thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Impaired renal function",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pulmonary thromboembolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hemorrhagic eruption",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F168252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Breast cancer or other estrogen- or progestin-dependent neoplasms (current or a history of), hepatic tumors or disease, cholestatic jaundice of pregnancy, jaundice with prior combination hormonal contraceptive use, pregnancy, undiagnosed abnormal uterine bleeding",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use is also contraindicated in women at high risk of arterial or venous thrombotic diseases including: Cerebrovascular disease, coronary artery disease, DVT or PE (current or history of)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F168236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breast cancer: The use of combination hormonal contraceptives has been associated with a slight increase in frequency of breast cancer; however, studies are not consistent. Use is contraindicated in women with (or history of) breast cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in women with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholestasis: Risk of cholestasis may be increased with previous cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipid effects: Combination hormonal contraceptives may affect serum triglyceride and lipoprotein levels. Estrogen compounds are generally associated with lipid effects such as increased HDL-cholesterol and decreased LDL-cholesterol. Triglycerides may also be increased; use with caution in patients with familial defects of lipoprotein metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Retinal vascular thrombosis: Estrogens may cause retinal vascular thrombosis; discontinue if migraine, loss of vision, proptosis, diplopia or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolism: May increase the risk of thromboembolism; discontinue use of combination hormonal contraceptives if an arterial or venous thrombotic event occurs. Women with inherited thrombophilias (eg, protein C or S deficiency) may have increased risk of venous thromboembolism (DeSancho, 2010; van Vlijmen, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaginal bleeding: Presentation of irregular, unresolving vaginal bleeding warrants further evaluation including endometrial sampling, if indicated, to rule out malignancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with risk factors for coronary artery disease (eg, hypertension, hypercholesterolemia, morbid obesity, diabetes, or women who smoke); may lead to increased risk of myocardial infarction. May have a dose-related risk of vascular disease and hypertension; women with hypertension should be encouraged to use a nonhormonal form of contraception.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use with caution in patients with depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diseases exacerbated by fluid retention: Use with caution in patients with diseases which may be exacerbated by fluid retention, including asthma, epilepsy, migraine, diabetes or renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gallbladder disease: May have a dose-related risk of gallbladder disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic adenomas: Extremely rare adenomas and focal nodular hyperplasia resulting in fatal intra-abdominal hemorrhage have been reported in association with long-term oral contraceptive use. Presentation of an abdominal mass, acute abdominal pain, or intra-abdominal bleeding warrants further evaluation to rule out source.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Combination hormonal contraceptives may be poorly metabolized in women with hepatic impairment. Discontinue if jaundice develops during therapy or if liver function becomes abnormal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Migraine: Use with caution in patients with a history of migraine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Women with renal disease should be encouraged to use a nonhormonal form of contraception.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thyroid replacement therapy: Estrogens may increase thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels. Women on thyroid replacement therapy may require higher doses of thyroid hormone while receiving estrogens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not for use prior to menarche.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Smokers:",
"     <b>",
"      [U.S. Boxed Warning]: The risk of cardiovascular side effects is increased in women who smoke cigarettes; risk increases with age (especially women &gt;35 years of age) and the number of cigarettes smoked; women who use combination hormonal contraceptives should be strongly advised not to smoke. Should not be used in patients &gt;35 years of age who smoke.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: Whenever possible, should be discontinued at least 4 weeks prior to and for 2 weeks following elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV infection protection: Oral contraceptives do not protect against HIV infection or other sexually-transmitted diseases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Laboratory changes: The use of estrogens and/or progestins may change the results of some laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). The dose, route, and the specific estrogen/progestin influences these changes. In addition, personal risk factors (eg, cardiovascular disease, smoking, diabetes, age) also contribute to adverse events; use of specific products may be contraindicated in women with certain risk factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Minimum effective dosage: The minimum dosage combination of estrogen/progestin that will effectively treat the individual patient should be used. New patients should be started on products containing  &le;0.035 mg of estrogen per tablet.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F168281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F168241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acitretin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Given the potential for progestin-only preparations to fail to prevent pregnancy during acitretin therapy, such products should not be relied upon. Alternative, nonhormonal forms of contraception must be employed during acitretin therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Progestins. Management: Progestin-containing contraceptives are not recommended; consider the use of alternative, nonhormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use of a non-hormone-based contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May decrease the serum concentration of Contraceptives (Progestins). Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Armodafinil: May decrease the serum concentration of Contraceptives (Estrogens). Management: The manufacturer recommends that patients use nonhormonal contraceptives, in addition to or in place of hormonal contraceptives, during and for one month following treatment with armodafinil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May decrease the serum concentration of Contraceptives (Progestins). Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a non-hormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Contraceptives (Estrogens) may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Contraceptives (Progestins) may increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): May decrease the serum concentration of Contraceptives (Estrogens). Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (including at least one nonhormonal form).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): May decrease the serum concentration of Contraceptives (Progestins). Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (including at least one nonhormonal form).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Contraceptives (Estrogens). Management: Administer estrogen-based oral contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Contraceptives (Progestins). Management: Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Patients receiving boceprevir, ribavirin, and peginterferon alfa should use two reliable forms of contraception.  Norethindrone/ethinyl estradiol may be used for one of these when norethindrone dose is at least 1 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Contraceptives (Progestins). This has been seen specifically with drospirenone. Boceprevir may increase the serum concentration of Contraceptives (Progestins). This has been seen specifically with norethindrone. Management: Patients receiving boceprevir, ribavirin, and peginterferon alfa should use two reliable forms of contraception.  Norethindrone/ethinyl estradiol may be used for one of these when norethindrone dose is at least 1 mg/day. Avoid drospirenone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Contraceptives (Progestins). Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloBAZam: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloBAZam: May decrease the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Contraceptives (Progestins). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colesevelam: May decrease the serum concentration of Ethinyl Estradiol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exenatide: May decrease the serum concentration of Contraceptives (Estrogens). Management: Administer oral contraceptives at least one hour prior to exenatide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exenatide: May decrease the serum concentration of Oral Contraceptive (Progestins). Management: Administer oral contraceptives at least one hour prior to exenatide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May decrease the serum concentration of Contraceptives (Progestins). Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal method of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May decrease the serum concentration of Contraceptives (Estrogens). The active metabolite aprepitant is likely responsible for this effect. Management: Alternative or additional methods of contraception should be used both during treatment with fosaprepitant or aprepitant and for at least one month following the last fosaprepitant/aprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May decrease the serum concentration of Contraceptives (Progestins). The active metabolite aprepitant is likely responsible for this effect. Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal means of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: May increase the metabolism of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use an alternative, nonhormonal form of contraception, or use an alternative to griseofulvin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Estrogenic Properties): May enhance the adverse/toxic effect of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Progestogenic Properties) (eg, Bloodroot, Yucca): May enhance the adverse/toxic effect of Progestins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Contraceptives (Estrogens) may decrease the serum concentration of LamoTRIgine.  Management: Monitor for increased serum concentrations/effects of lamotrigine in patients in whom a hormonal contraceptive is discontinued/dose decreased (this includes during a pill-free week). A reduced dosage of lamotrigine may be needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: May decrease the serum concentration of Contraceptives (Progestins). Management: Women using progestin-only &ldquo;minipill&rdquo; products may be at risk for contraceptive failure; it is unclear if other progestin-containing products would be significantly impacted.  Alternative, non-hormonal, means of contraception are recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Contraceptives (Progestins). Mifepristone may increase the serum concentration of Contraceptives (Progestins). Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Contraceptives (Estrogens). Mifepristone may increase the serum concentration of Contraceptives (Estrogens). Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Modafinil: May decrease the serum concentration of Contraceptives (Estrogens). Management: The manufacturer recommends that patients use nonhormonal contraceptives, in addition to or in place of hormonal contraceptives, during and for one month following treatment with modafinil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: May decrease the serum concentration of Contraceptives (Estrogens). Average AUC values were unchanged, but there was evidence of substantial patient-to-patient variability in response to this combination. Management: Women of childbearing potential who are receiving mycophenolate mofetil should consider using an alternative and/or additional form of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: May decrease the serum concentration of Contraceptives (Progestins). Management: Use of an additional or alternative (nonhormonal) method of contraception should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Contraceptives (Estrogens). Management: Use of an alternative, nonhormonal form of contraception during nafcillin therapy is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Contraceptives (Progestins). Management: Instruct patients receiving nevirapine to use an alternative or additional nonhormonal contraceptive. Nevirapine product labeling however suggests that depo-medroxyprogesterone acetate may be used as a sole method of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): May enhance the thrombogenic effect of Estrogen Derivatives. NSAID (COX-2 Inhibitor) may increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. Estrogen Derivatives may diminish the therapeutic effect of Ospemifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: May decrease the serum concentration of Contraceptives (Progestins). Management: Contraceptive failure is possible.  Use of an additional or alternative, nonhormonal method of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May decrease the serum concentration of Contraceptives (Progestins). Management: Patients should use an alternative, non-hormonal based form of contraception for the duration of concurrent perampanel.  Both oral and non-oral progestin-based contraceptives are likely to be impacted by this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal means of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: This combination may be used with caution only if the moderate CYP1A2 inhibitor does not significantly inhibit other CYP enzymes and the patient is not taking any other drugs that do significantly inhibit other specific CYP enzymes.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use oral contraceptives containing at least 35mcg ethinyl estradiol with atazanavir/ritonavir, or no more than 30mcg in patients receiving atazanavir alone. Use of an alternative, non-hormonal contraceptive is recommended with other protease inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Indinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: May decrease the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: May diminish the therapeutic effect of Contraceptives (Progestins). Retinoic Acid Derivatives may decrease the serum concentration of Contraceptives (Progestins). Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives.  Particularly, microdosed progesterone-only preparations may be inadequately effective.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: May diminish the therapeutic effect of Contraceptives (Estrogens). Two forms of contraception are recommended in females of child-bearing potential during retinoic acid derivative therapy.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Adapalene; Alitretinoin; Tretinoin (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rufinamide: May decrease the serum concentration of Ethinyl Estradiol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selegiline: Contraceptives (Estrogens) may increase the serum concentration of Selegiline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selegiline: Contraceptives (Progestins) may increase the serum concentration of Selegiline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Consider an alternative to St John's wort if possible.  If this combination is used, an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Consider using a product other than St John's wort.  Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Two different nonhormonal forms of contraception are required for women of childbearing potential taking telaprevir.  Hormonal contraceptives may be less effective during concurrent telaprevir and for up to 2 weeks after telaprevir discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Contraceptives (Progestins). Management: Two different nonhormonal forms of contraception are required for women of childbearing potential taking telaprevir.  Hormonal contraceptives may be less effective during concurrent telaprevir and for up to 2 weeks after telaprevir discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Contraceptives (Estrogens) may increase the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Estrogen Derivatives may enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives.  Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: Contraceptives (Estrogens) may increase the serum concentration of TiZANidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Risk appears greatest for higher topiramate doses (200 mg/day or greater).  Some have recommended using at least 50 mcg/day of ethinyl estradiol, but the effectiveness of this is unclear.  Consider a nonhormonal form of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: May decrease the serum concentration of Contraceptives (Progestins). Management: Caution patients that this combination may be associated with reduced contraceptive effectiveness.  Consider adding an additional (non-hormonal) contraceptive method.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tranexamic Acid: Contraceptives (Progestins) may enhance the thrombogenic effect of Tranexamic Acid.  Management: Ensure that the potential benefits of concurrent therapy outweigh the increased risk of potential thrombosis that accompanies use of tranexamic acid with hormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tranexamic Acid: Contraceptives (Estrogens) may enhance the thrombogenic effect of Tranexamic Acid.  Management: Ensure that the potential benefits of concurrent therapy outweigh the increased risk of potential thrombosis that accompanies use of tranexamic acid with hormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Contraceptives (Estrogens) may diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Contraceptives (Progestins) may diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.  Management: When possible, concomitant hormonal contraceptives and coumarin derivatives should be avoided in order to eliminate the risk of thromboembolic disorders.  Consider using an alternative, nonhormonal contraceptive.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May decrease the metabolism of Contraceptives (Estrogens). Contraceptives (Estrogens) may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Contraceptives (Progestins). Contraceptives (Progestins) may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F168262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine. Grapefruit juice increases ethinyl estradiol concentrations and would be expected to increase progesterone serum levels as well; clinical implications are unclear.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease levels. Herbs with estrogenic properties may enhance the adverse/toxic effect of estrogen derivatives; examples include alfalfa, black cohosh, bloodroot, hops, kudzu, licorice, red clover, saw palmetto, soybean, thyme, wild yam, yucca. Herbs with progestogenic properties may enhance the adverse/toxic effect of progestins; examples include bloodroot, chasteberry, damiana, oregano, yucca.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F168243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F168254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pregnancy should be ruled out prior to treatment and discontinued if pregnancy occurs. In general, the use of combination hormonal contraceptives when inadvertently taken early in pregnancy have not been associated with teratogenic effects. Hormonal contraceptives may be less effective in obese patients. An increase in oral contraceptive failure was noted in women with a BMI &gt;27.3 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     . Similar findings were noted in patients weighing &ge;90 kg (198 lb) using the contraceptive patch.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to increased risk of venous thromboembolism (VTE) postpartum, combination hormonal contraceptives should not be started in any woman &lt;21 days following delivery. Women without risk factors for VTE and who are not breast-feeding may start combination hormonal contraceptives during 21-42 days postpartum. After 42 days postpartum, restrictions for use are not related to postpartum status and should be based on other medical conditions (CDC,  2011).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F168275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F168255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Jaundice and breast enlargement in the nursing infant have been reported following the use of combination hormonal contraceptives. May decrease the quality and quantity of breast milk; a nonhormonal form of contraception is recommended (per manufacturer). Postpartum risk status for VTE should be considered when initiating combination hormonal contraceptives after delivery. Combined hormonal contraceptives should not be started &lt;21 days postpartum due to increased risk of VTE. Risk of VTE is still elevated in breast-feeding women until ~42 days postpartum and is greater in women with additional risk factors. After 42 days postpartum, restrictions for use are not related to postpartum VTE risk and should be based on other medical conditions (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F168256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with food at same time each day.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Kelnor 1/35 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-35 mg-mcg (28): $29.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Zovia 1/35E (28) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-35 mg-mcg (28): $29.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Zovia 1/50E (28) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-50 mg-mcg (28): $33.29",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F168245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Before starting therapy, a physical exam with reference to the breasts and pelvis are recommended, including a Papanicolaou smear. Exam may be deferred if appropriate; pregnancy should be ruled out prior to use. Monitor patient closely for loss of vision, sudden onset of proptosis, diplopia, migraine; blood pressure; signs and symptoms of thromboembolic disorders; signs or symptoms of depression; glycemic control in patients with diabetes; lipid profiles in patients being treated for hyperlipidemias. Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F168257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ovulen 50 (NL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F168235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Combination hormonal contraceptives inhibit ovulation via a negative feedback mechanism on the hypothalamus, which alters the normal pattern of gonadotropin secretion of a follicle-stimulating hormone (FSH) and luteinizing hormone by the anterior pituitary. The follicular phase FSH and midcycle surge of gonadotropins are inhibited. In addition, combination hormonal contraceptives produce alterations in the genital tract, including changes in the cervical mucus, rendering it unfavorable for sperm penetration even if ovulation occurs. Changes in the endometrium may also occur, producing an unfavorable environment for nidation. Combination hormonal contraceptive drugs may alter the tubal transport of the ova through the fallopian tubes. Progestational agents may also alter sperm fertility.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F168251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ethynodiol diacetate",
"     </b>",
"     (converted to norethindrone)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metabolism: Hepatic conjugation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Half-life elimination: Terminal: 5-14 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     See Norethindrone monograph.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/22/12649/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burkman R, Schlesselman JJ, and Zieman M, &ldquo;Safety Concerns and Health Benefits Associated With Oral Contraception,&rdquo;",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2004, 190(4 Suppl):5-22.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: Revised Recommendations for the Use of Contraceptive Methods During the Postpartum Period,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2011, 60(26):878-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/22/12649/abstract-text/21734635/pubmed\" id=\"21734635\" target=\"_blank\">",
"        21734635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeSancho MT, Dorff T, and Rand JH, \"Thrombophilia and the Risk of Thromboembolic Events In Women on Oral Contraceptives and Hormone Replacement Therapy,\"",
"      <i>",
"       Blood Coagul Fibrinolysis",
"      </i>",
"      , 2010, 21(6):534-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/22/12649/abstract-text/20581664/pubmed\" id=\"20581664\" target=\"_blank\">",
"        20581664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents. Panel on Clinical Practices for Treatment of HIV Infection,&rdquo; August 13, 2001. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holt VL, Scholes D, Wicklund KG, et al, &ldquo;Body Mass Index, Weight, and Oral Contraceptive Failure Risk,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2005, 105(1):46-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/22/12649/abstract-text/15625141/pubmed\" id=\"15625141\" target=\"_blank\">",
"        15625141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Orme ML, Back DJ, and Breckenridge AM, &ldquo;Clinical Pharmacokinetics of Oral Contraceptive Steroids,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1983, 8(2):95-136.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/22/12649/abstract-text/6342899/pubmed\" id=\"6342899\" target=\"_blank\">",
"        6342899",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shenfield GM and Griffin JM, &ldquo;Clinical Pharmacokinetics of Contraceptive Steroids. An Update,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1991, 20(1):15-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/22/12649/abstract-text/2029800/pubmed\" id=\"2029800\" target=\"_blank\">",
"        2029800",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sitruk-Ware R and Nath A, \"Metabolic Effects of Contraceptive Steroids,\"",
"      <i>",
"       Rev Endocr Metab Disord",
"      </i>",
"      , 2011, 12(2):63-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/22/12649/abstract-text/21538049/pubmed\" id=\"21538049\" target=\"_blank\">",
"        21538049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Vlijmen EF, Veeger NJ, Middeldorp S, et al, \"Thrombotic Risk During Oral Contraceptive Use and Pregnancy in Women With Factor V Leiden or Prothrombin Mutation: A Rational Approach to Contraception,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(8):2055-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/22/12649/abstract-text/21659542/pubmed\" id=\"21659542\" target=\"_blank\">",
"        21659542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9434 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-84F2B57B49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_22_12649=[""].join("\n");
var outline_f12_22_12649=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708761\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168266\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168267\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168286\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168270\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168280\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168271\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168272\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168247\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168232\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168249\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168248\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168283\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168293\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168284\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168252\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168236\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168281\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168241\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168262\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168243\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168254\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168275\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168255\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168256\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524565\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168245\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168257\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168235\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168251\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9434\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9434|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/2/11302?source=related_link\">",
"      Ethinyl estradiol and ethynodiol diacetate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_22_12650="Endocrine changes with aging";
var content_f12_22_12650=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endocrine changes with aging",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/22/12650/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/22/12650/contributors\">",
"     S Mitchell Harman, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/22/12650/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/22/12650/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/22/12650/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/22/12650/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/22/12650/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/22/12650/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the 19",
"    <sup>",
"     th",
"    </sup>",
"    century there have been sporadic attempts to attribute the changes of aging to one or another endocrine deficit and efforts to reverse these changes with a variety of endocrine therapies. This search for a hormonal \"fountain of youth\" continues today with, as an example, the widespread use of dehydroepiandrosterone (DHEA) as a \"nutritional supplement.\" Of greater clinical significance is the increasing practice of \"off-label\" prescribing of human growth hormone (hGH) and potent androgenic steroids for age-related declines in",
"    <span class=\"nowrap\">",
"     GH/IGF-1",
"    </span>",
"    and testosterone, termed respectively, \"somatopause\" and \"andropause.\" The evidence for age-related changes in endocrine function and their clinical consequences are reviewed here; disease-related changes are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4314?source=see_link\">",
"     \"Overview of testosterone deficiency in elderly men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/263?source=see_link\">",
"     \"Dehydroepiandrosterone and its sulfate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1833?source=see_link\">",
"     \"Growth hormone deficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY OF AGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complexity of the aging process precludes simplistic formulations that equate aging with hormone deficiency. Biological aging is characterized by a progressive and, to a considerable extent, predictable loss of coordinated cell and tissue function, such that the organism becomes gradually less fit to reproduce and survive. The rate of this process is species-specific and changes are manifested across multiple organs and systems. Deterioration of function is heterogeneous among systems and individuals and is generally detectable first as a loss of reserve capacity and ability to restore homeostasis under stress, then later by altered function at rest.",
"   </p>",
"   <p>",
"    The basic mechanisms underlying aging are unknown. The best available evidence is consistent with the accumulation of a variety of (unrepaired) biochemical alterations that impair the function of nucleic acids, proteins, and lipid membranes. These alterations probably include oxidation by free radicals [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/1\">",
"     1",
"    </a>",
"    ], but also non-enzymatic glycosylation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/2\">",
"     2",
"    </a>",
"    ], and epigenetic changes such as DNA methylation and histone acetylation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/3\">",
"     3",
"    </a>",
"    ]. The extent to which differentiated cells are affected by aging determines physiological function, while the extent to which reserve (stem and precursor) cells are affected determines the capacity to replace damaged differentiated cells and repair tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/4\">",
"     4",
"    </a>",
"    ]. Some studies have suggested the presence of circulating factors in aged organisms that inhibit stem cell mobilization, and compromise damage repair [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. However, the biochemical identities of the cytokines involved remain to be determined.",
"   </p>",
"   <p>",
"    A well-described phenomenon of aging is a widely distributed deterioration of signal transduction efficiency. Examples include a reduction in the vasodilatory response of the endothelium to estrogen, possibly related to the progressive methylation of the estrogen receptor gene (an epigenetic change) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/6\">",
"     6",
"    </a>",
"    ], and reduced Leydig cell responsiveness to gonadotropin stimulation (probably due to altered cell membrane biochemistry) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Endocrine changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In considering changes in endocrine function in older people, it is important to distinguish between the effects of aging per se on endocrine physiology and those caused by age-related illness, given the high prevalence of disorders, both symptomatic and asymptomatic, in the elderly. The distinction is simple in concept but not in practice.",
"   </p>",
"   <p>",
"    As a practical approach, an endocrine change that occurs in a significant fraction of older persons, especially if it can be documented in persons with no identifiable serious chronic illness, is likely to be due to aging. On the other hand, when a change is limited to a minority of older persons, it is probably disease-related.",
"   </p>",
"   <p>",
"    The distinction between what is age-related and what is disease-related is difficult due to the problem of defining study populations free of age-related illnesses as \"normal.\" Individuals do not all age at the same rate so that unusually healthy older populations may be biased toward individuals who are biologically \"younger\" than their chronologic age.",
"   </p>",
"   <p>",
"    Several general comments about endocrine changes with aging are relevant:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The only endocrine system for which there is a well-defined, abrupt, and universal change in function with age is the hypothalamic-pituitary-gonadal axis in women.",
"     </li>",
"     <li>",
"      The function of the growth hormone insulin-like growth factor 1 (IGF-1) system, the male hypothalamic-pituitary-gonadal axis, and the portion (zona reticularis) of the adrenal cortex that synthesizes dehydroepiandrosterone all decline progressively with age in most people. Age-adjusted ranges of normal values for serum IGF-1, total and free or bioavailable testosterone, and dehydroepiandrosterone concentrations can be defined, but whether these values are physiologically optimal is unknown.",
"     </li>",
"     <li>",
"      The secretion of some other hormones is also altered with age, but changes are much less predictable, and there are no well-defined, age-adjusted normal values.",
"     </li>",
"     <li>",
"      The action of some hormones decreases with age; increased hormonal secretion may or may not compensate for such decreases in tissue responsiveness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HYPOTHALAMIC-PITUITARY FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are shifts in the timing and magnitude of the circadian rhythms of corticotropin (ACTH), thyrotropin (TSH), and growth hormone (GH) in normal older persons [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/9\">",
"     9",
"    </a>",
"    ]. Most of these changes are small, but for GH, and possibly for ACTH, the changes may be clinically important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Changes in growth hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;GH secretion and serum GH concentrations fall with age, both basally and in response to provocative stimuli, and there is a parallel decrease in serum concentrations of IGF-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. The fall in GH secretion is due to a decrease in hypothalamic GH-releasing hormone (GHRH) secretion, as well as a decrease in pituitary responsiveness to GHRH (decreased GH pulse amplitude) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/11,13,14\">",
"     11,13,14",
"    </a>",
"    ]. The precise roles of the three peptide factors (GH-releasing hormone, somatostatin, and ghrelin), whose interactions modulate GH secretion, have yet to be elucidated, but GH deficiency does not appear to be due to reductions in ghrelin, since levels of this enterokine secretagogue actually increase in the elderly. Low physical fitness and higher adiposity also contribute to the decrease in GH secretion in older subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43030?source=see_link\">",
"     \"Physiology of growth hormone\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/7/3192?source=see_link\">",
"     \"Physiology of insulin-like growth factor I\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because most GH is secreted during slow-wave sleep, the relationship of GH to age-associated sleep disturbances is also an issue. Older adults maintain a diurnal rhythm of GH secretion with amplification of nocturnal peaks, but with lower amplitudes than seen in the young. Pharmacologically induced increases in stage III and IV slow wave sleep enhances GH pulsatile episodes in young adults [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/16\">",
"     16",
"    </a>",
"    ], but whether this would be the case in the elderly remains unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Growth hormone therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observations that some of the decrease in lean body mass and in bone density in older subjects can be reversed by administration of GH lends support to the concept that their lower GH secretion and IGF-1 production have clinical consequences [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/17\">",
"     17",
"    </a>",
"    ]. In a randomized trial of recombinant human GH (rhGH) replacement with or without sex steroid replacement in 131 older men and women (ages 65 to 88), the following changes were seen [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lean body mass increased and fat mass decreased with rhGH treatment in both men and women.",
"     </li>",
"     <li>",
"      The addition of estrogen-progestin therapy to rhGH provided no additional benefit in women, while a trend towards a greater increase in lean body mass was seen with the addition of testosterone in men.",
"     </li>",
"     <li>",
"      A marginal increase in muscle strength and a significant increase in V02max was seen with combined rhGH-sex steroid replacement in men, but not women. The muscle strength and V02max changes in men were directly related to changes in lean body mass, and were more pronounced with combined therapy than with testosterone alone (and marginally greater than with rhGH alone).",
"     </li>",
"     <li>",
"      Significant side effects occurred in both men and women in the growth hormone groups (with or without sex steroids), including edema, carpal tunnel syndrome, and arthralgias. Diabetes and glucose intolerance developed more commonly in rhGH-treated men than in those not receiving growth hormone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In other smaller rhGH studies in the elderly, the changes in lean body mass and bone density were minimal or inconsistent, or added little to the effects of exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. In a follow-up report from the trial cited above, total body protein synthesis increased in men treated with rhGH plus testosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/22\">",
"     22",
"    </a>",
"    ]; however, the rate of muscle protein synthesis was not increased by rhGH in another study [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/23\">",
"     23",
"    </a>",
"    ]. In a study in which GH secretion and IGF-1 were increased by administration of a GH secretagogue, significant improvements were observed in some functional exercise measures as well as lean body mass [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse effects of rhGH replacement in the elderly have also been reported in other studies. As an example, in a trial of rhGH replacement in 1123 patients with adult-onset GH deficiency, results in the subset of 258 patients older than 60 showed more frequent adverse effects and smaller improvements in LBM and body fat mass compared with younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a systematic review and meta-analysis of 18 randomized trials of GH therapy in 220 elderly men and women (12 trials comparing GH versus no GH, and six comparing GH plus lifestyle changes versus lifestyle changes only), the following results were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean age, body mass index, initial GH dose, and treatment duration were 69 years, 28",
"      <span class=\"nowrap\">",
"       kg/m2,",
"      </span>",
"      14",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      body weight, and 27 weeks, respectively.",
"     </li>",
"     <li>",
"      Lean body mass increased and fat mass decreased (mean change +2.1 kg and -2.1 kg, respectively). There was no significant change in weight.",
"     </li>",
"     <li>",
"      Total cholesterol decreased, but the change was not significant after adjustment for changes in body composition. Bone mineral density and other lipids did not change.",
"     </li>",
"     <li>",
"      Patients receiving GH were significantly more likely to develop soft tissue edema, arthralgias, carpal tunnel syndrome, and gynecomastia.",
"     </li>",
"     <li>",
"      A nonsignificant increase in the risk of developing impaired fasting glucose or type 2 diabetes was seen in the GH group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, although combined rhGH-sex steroid supplementation appears to exert beneficial effects on body composition in both men and women, and possibly improve muscle strength and V02 max in men, significant adverse effects occur. Of further concern is the fact that mice with disrupted GH secretion or absent GH receptors live longer than normal mice, an observation that challenges the idea that GH is an anti-aging hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the above, rhGH administration should be reserved for patients with documented GH deficiency. The topic of growth hormone deficiency in adults of all ages is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1833?source=see_link\">",
"     \"Growth hormone deficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     VASOPRESSIN AND WATER BALANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal responsiveness to vasopressin is reduced in older as compared with younger persons, making them more vulnerable to water deprivation. The vasopressin response to osmotic stimulation may [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/29\">",
"     29",
"    </a>",
"    ] or may not [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/30\">",
"     30",
"    </a>",
"    ] be increased in elderly men and women, whereas the vasopressin response to volume depletion, a response mediated via baroreceptors, is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/31\">",
"     31",
"    </a>",
"    ]. There is a parallel decrease in thirst in response to osmotic stimulation. As a result of the decreases in thirst and in renal responsiveness to vasopressin, older subjects can become more easily dehydrated, even if vasopressin secretion rises [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Paradoxically, hyponatremia is also a common problem in the elderly, particularly in women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/33\">",
"     33",
"    </a>",
"    ]. The extent to which this represents hypersecretion of vasopressin with water retention (SIADH) versus renal tubular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/34\">",
"     34",
"    </a>",
"    ] is unclear, but both conditions occur. Some hyponatremic elderly are relatively dehydrated and mineralocorticoid deficient [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/35\">",
"     35",
"    </a>",
"    ]. Therefore, mineralocorticoid-responsive hyponatremia must be carefully differentiated from SIADH in elderly subjects. Data suggest that chronic benign hyponatremia of the elderly is associated with accelerated calcium loss from bone and is thus more problematic than previously suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Consideration should therefore be given to assessment for and treatment of osteoporosis in the elders with low serum sodium levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PINEAL FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melatonin secretion is lower in older as compared with younger subjects, particularly the surge in melatonin secretion that occurs during sleep at night. This decrease is a possible cause of poor sleep in many older persons, a conclusion supported by the improvement in sleep that occurs in older persons given small doses of melatonin (0.3 mg) several hours before retiring [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13034?source=see_link\">",
"     \"Physiology and clinical use of melatonin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ADRENOCORTICAL FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somewhat variable changes in secretion on the three major adrenocortical hormones have been described in normal older subjects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cortisol",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are variable age-related changes in ACTH and cortisol secretion and in the effects of cortisol on ACTH secretion or of ACTH on cortisol secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Individual studies of various aspects of ACTH and cortisol secretion have revealed the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum cortisol concentrations may vary more within a 24-hour period in older than younger subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mean 24-hour serum cortisol concentrations are 20 to 50 percent higher in both older men and women [",
"      <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The evening nadir in serum cortisol concentrations may be higher and earlier in older persons [",
"      <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/43,44\">",
"       43,44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The sensitivity of ACTH and cortisol secretion to inhibition by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      is similar in older and younger women [",
"      <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/40\">",
"       40",
"      </a>",
"      ], but the inhibition may be slower in onset [",
"      <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serum cortisol concentrations increase more in response to exogenous ACTH in older women [",
"      <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serum cortisol concentrations increase similarly in response to fasting in older and younger men [",
"      <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The serum cortisol responses to stress are prolonged in older subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These changes, variable and often small, do not seem to have any effects on the pituitary-adrenal responses to acute illness. They may, however, have clinically important chronic effects. For instance, the change in evening cortisol secretion has been thought to be related to sleep disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/43\">",
"     43",
"    </a>",
"    ]. Furthermore, among older subjects, higher cortisol secretion, as measured by mean serum cortisol concentrations or urinary cortisol excretion, is associated with poorer memory in women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/46\">",
"     46",
"    </a>",
"    ], lower bone density in men [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/47\">",
"     47",
"    </a>",
"    ], and an increase in fractures in both men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An association has been reported in elderly men between higher 24-hour integrated cortisol secretion and greater body fat [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/49\">",
"     49",
"    </a>",
"    ]. An increase in abdominal fat (and insulin resistance) and a decrease in lean body mass (findings similar to those seen with Cushing's syndrome), are typical changes in the elderly. However, it is not known if an increase in mean integrated exposure to cortisol contributes to these changes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Aldosterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The secretion rate and serum concentrations of aldosterone fall with age [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/50\">",
"     50",
"    </a>",
"    ]; by about age 70 years the decreases can be as much as 50 percent. The proximate cause of these decreases is a decrease in renin secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/51\">",
"     51",
"    </a>",
"    ]. This decrease, when marked, can result in hypoaldosteronism, particularly in patients with mild renal failure, with urinary sodium wasting, hyponatremia, and hyperkalemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\"",
"    </a>",
"    .) A raised serum concentration of atrial natriuretic hormone may also contribute to urinary sodium wasting in older subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decrease in serum aldosterone concentrations and urinary aldosterone excretion with age is sufficient that values in older patients suspected of having primary aldosteronism may be within the normal ranges cited by most laboratories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dehydroepiandrosterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dehydroepiandrosterone (DHEA) and its sulfate are the most abundant circulating steroids, yet have no certain function except as precursors of active androgens and estrogens. The secretion and serum concentrations of both DHEA and its sulfate decrease markedly with age from the third decade onward [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/53-55\">",
"     53-55",
"    </a>",
"    ], so that in 70 to 80 year olds serum concentrations of both are about 20 percent of those in persons 20 to 30 years old. Higher endogenous levels of DHEA have been associated with better health and longevity, and DHEA-sulfate levels have recently been reported to be lower in frail than in healthy elderly patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/263?source=see_link\">",
"     \"Dehydroepiandrosterone and its sulfate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether the decline in DHEA production is clinically important is not known. Given the marked decline with age, many have speculated that administration of DHEA might reverse some of the changes in body composition and behavior that occur with aging [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/55\">",
"     55",
"    </a>",
"    ]. A placebo-controlled trial in which doses of DHEA sufficient to increase levels to those typical of younger persons were administered to normal older men and women for two years showed no improvement in body composition, oxygen consumption, muscle strength, or insulin sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/57\">",
"     57",
"    </a>",
"    ]. These results are similar to those reported in earlier treatment studies, yet DHEA still has vocal advocates. Because it is sold as a food supplement, DHEA can be, and is, taken by many as an anti-aging remedy. We suggest against the use of DHEA for this purpose.",
"   </p>",
"   <p>",
"    Available data are consistent with the conclusions that the decline in serum DHEA and DHEA-sulfate concentrations may be a marker for biological aging but that DHEA &ldquo;deficiency&rdquo; has no direct clinical consequences and that, in older persons, administration of DHEA has no well-defined benefits. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/263?source=see_link&amp;anchor=H11#H11\">",
"     \"Dehydroepiandrosterone and its sulfate\", section on 'Anti-aging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ADRENOMEDULLARY FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum norepinephrine concentrations are higher in older than younger subjects, whereas those of epinephrine are either the same or slightly lower [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. The higher serum norepinephrine concentrations reflect a higher level of activity of the sympathetic nervous system, not the adrenal medulla [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/60,61\">",
"     60,61",
"    </a>",
"    ], and are probably compensatory responses to decreases in the responsiveness of at least some tissues to norepinephrine [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PITUITARY-THYROID FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The volume of the thyroid gland increases slightly with age [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/64\">",
"     64",
"    </a>",
"    ]. There are no age-related changes in serum total or free thyroxine concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/65-68\">",
"     65-68",
"    </a>",
"    ]. Serum thyroxine-binding globulin concentrations decline slightly, those of transthyretin increase [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/69\">",
"     69",
"    </a>",
"    ]; therefore, there is no net change in overall thyroxine binding. Thyroxine clearance does decrease modestly with age [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/70\">",
"     70",
"    </a>",
"    ], but so does thyroxine production, due to a decrease in TSH secretion. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Thyrotropin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Similarly, serum triiodothyronine concentrations in general do not decrease with age in carefully selected healthy subjects. However, among groups of less carefully selected older subjects, some have lower serum triiodothyronine concentrations than do normal young subjects. These older subjects probably have some nonthyroidal illness that reduces extrathyroidal conversion of thyroxine to triiodothyronine [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among the healthy &ldquo;oldest old&rdquo; (centenarians), serum triiodothyronine concentrations are slightly lower than in normal young subjects, suggesting an age- rather than illness-related change [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/68,72\">",
"     68,72",
"    </a>",
"    ], but higher than in non-centenarian elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/73\">",
"     73",
"    </a>",
"    ], suggesting that low T3 may be a marker for physiological age, illness,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    frailty. In short, measurements of serum triiodothyronine are even less useful as an indicator of hypothyroidism in older subjects than they are in younger subjects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link\">",
"     \"Diagnosis of and screening for hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link&amp;anchor=H9#H9\">",
"     \"Diagnosis of and screening for hypothyroidism\", section on 'Effectiveness'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reduction in thyroxine clearance noted above may lead to a decrease in dose requirement for thyroid hormone replacement as patients with hypothyroidism age [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/74\">",
"     74",
"    </a>",
"    ]. Thus, in general, the starting dose of thyroid hormone should be lower (0.05",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in the elderly and patients on chronic thyroid replacement should be evaluated at least yearly for possible dose reductions as they reach their sixties and beyond. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of hypothyroidism\", section on 'Older patients or those with coronary heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Thyrotropin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The range of serum TSH values in older subjects who have normal serum free thyroxine concentrations is slightly broader than in younger subjects, especially women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/75-78\">",
"     75-78",
"    </a>",
"    ]. The percentages of persons with low TSH levels rises from 2 to 3 percent to 5 to 6 percent, and with high TSH levels from 2 to 3 percent to 8 to 12 percent as age increases from under age 50 to over age 60 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/79\">",
"     79",
"    </a>",
"    ]. Some of this broadening is likely due to the inclusion of persons with mild chronic autoimmune thyroiditis on the one hand and small nontoxic nodular goiters on the other. The amplitude of the nocturnal pulses of TSH secretion, which accounts for the majority of 24-hour TSH secretion, is less in older than in younger subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/80\">",
"     80",
"    </a>",
"    ]. This decrease probably accounts for the decrease in thyroxine secretion that occurs in response to the decrease in thyroxine clearance in older persons [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H528468\">",
"    <span class=\"h2\">",
"     Thyroid disease in the elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the above, low levels of TSH by ultrasensitive assay in the elderly should be considered as possible evidence of hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/81\">",
"     81",
"    </a>",
"    ]. Antithyroid antibodies and hyperthyroidism become more common with increasing age [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/79,82\">",
"     79,82",
"    </a>",
"    ], but the diagnosis is less apparent because older patients frequently lack characteristic hypermetabolic symptoms (heat intolerance, sinus tachycardia, sweating, tremor), with more common symptoms in patients over 65 being fatigue, muscle weakness, weight loss, and atrial arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. Elevated thyroid hormone also causes accelerated bone loss, so thyroid function testing should be done in patients (especially males) with osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of the clinical manifestations of hyperthyroidism in adults\", section on 'Geriatric hyperthyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is also an increasing prevalence of high levels of thyroid stimulating hormone (TSH) with age, particularly in postmenopausal women, indicating subclinical hypothyroidism estimated as high as 23 percent in some series [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/85\">",
"     85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3850?source=see_link\">",
"     \"Subclinical hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mild thyroid failure has been associated with depression, memory loss,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cognitive impairment in the elderly in some [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/86,87\">",
"     86,87",
"    </a>",
"    ] but not other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/88\">",
"     88",
"    </a>",
"    ]. In a trial of thyroid replacement in patients with mildly elevated TSH and normal T4 levels,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    treatment improved serum LDL cholesterol, brachial artery flow-mediated dilation, symptoms of fatigue, and the waist-hip ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/89\">",
"     89",
"    </a>",
"    ]. While it may be argued that routine screening for hypothyroidism in the elderly is warranted based upon these findings, the clinical utility of this approach is not established. In one report, elevated TSH concentrations were not associated with adverse outcomes in the oldest individuals when detected by screening alone [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/90\">",
"     90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link&amp;anchor=H9#H9\">",
"     \"Diagnosis of and screening for hypothyroidism\", section on 'Effectiveness'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PITUITARY-GONADAL FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are age-related decreases in not only ovarian but also testicular function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian secretion of estrogens and, to a lesser extent, androgens decreases and secretion of follicle-stimulating hormone and luteinizing hormone increases rather abruptly in about the sixth decade in women. These changes, the clinical changes that accompany them, and treatment are considered elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15720?source=see_link\">",
"     \"Ovarian development and failure (menopause) in normal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44761?source=see_link\">",
"     \"Clinical manifestations and diagnosis of menopause\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postmenopausal women have high serum follicle-stimulating hormone and luteinizing hormone concentrations, although the values gradually decline after about age 75 years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Men",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the majority of men, testicular function declines gradually with age. In longitudinal studies, the rate of decrease of circulating testosterone (T) has been observed to be relatively constant in men from their twenties onward at a rate just over 1 percent per year for total T and nearly 2 percent for non-SHBG bound or free T. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4314?source=see_link\">",
"     \"Overview of testosterone deficiency in elderly men\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum testosterone concentrations average about 100",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (34.7",
"    <span class=\"nowrap\">",
"     pmol/L)",
"    </span>",
"    lower in men aged 80 years or older than in young men. Because serum sex hormone-binding globulin concentrations increase with age, older men have a greater decline in serum free testosterone concentrations than in serum total testosterone concentrations. This decline is sometimes referred to as \"andropause.\" However, unlike menopause, where complete estrogen deficiency with known clinical consequences occurs, the decline in androgens in aging men varies from modest to severe and has unclear clinical consequences. It is of note that more than 70 percent of men over 70 years of age have free T levels consistent with hypogonadism [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/92\">",
"     92",
"    </a>",
"    ]. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4314?source=see_link\">",
"     \"Overview of testosterone deficiency in elderly men\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sperm production is stable from soon after the completion of puberty to about age 70 years, after which it declines progressively by about 50 percent by age 90 years. This is accompanied by tubular fibrosis, shrinkage of testicular volume, and modest elevations of FSH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/3/31800?source=see_link\">",
"     \"Male reproductive physiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk-benefit ratio for T treatment of elderly men with low testosterone levels remains uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4314?source=see_link\">",
"     \"Overview of testosterone deficiency in elderly men\"",
"    </a>",
"    .) Modest gains in bone density, muscle mass, and strength have been observed. In addition, some reports have emphasized decreases in central adiposity and insulin resistance and improvements in libido and erectile function [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/93\">",
"     93",
"    </a>",
"    ]. These gains need to be weighed against adverse effects on circulating lipids, with potential for increased cardiovascular disease risk, and possible risks of polycythemia, worsened sleep apnea, and even prostate cancer. A longitudinal follow-up study found that low T in older men is associated with increased risk of death over the following 20 years, independent of usual risk factors and pre-existing health conditions, but partially related to the inflammatory markers IL-6 and CRP [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/94\">",
"     94",
"    </a>",
"    ], a conclusion also supported by a cohort study in a hospital population [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another potentially relevant issue is preservation of cognition. Some studies have suggested that higher free T levels are associated with better cognitive function [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/96\">",
"     96",
"    </a>",
"    ] or lower risk of Alzheimer&rsquo;s disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/97\">",
"     97",
"    </a>",
"    ], with an uncertain interaction with Apo-E genotype [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. Elderly men treated with transdermal T have been reported to have better scores on selected tests of cognition and memory [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/100\">",
"     100",
"    </a>",
"    ], whereas men taking intramuscular T have been found to have decreased verbal memory and altered relative activity in medial temporal and prefrontal regions. The latter findings suggest detrimental effects of supraphysiological testosterone supplementation on CNS function [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     CALCIOTROPIC HORMONE PRODUCTION AND CALCIUM BALANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are modest but definite changes with age in calciotropic hormone production and calcium balance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Parathyroid hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum parathyroid hormone (PTH) concentrations are slightly higher in older as compared with younger subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/102\">",
"     102",
"    </a>",
"    ]. The likely cause of this increase is a fall in serum calcium concentration due to mild vitamin D deficiency and also phosphate retention caused by declining renal function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Vitamin D",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild vitamin D deficiency is common among older subjects, for several reasons, including decreased dietary vitamin D intake, decreased vitamin D absorption, decreased sun exposure, decreased generation of endogenous vitamin D during sun exposure, and decreased conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D in the kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/103\">",
"     103",
"    </a>",
"    ]. In addition, older subjects may have resistance to the action of 1,25,-dihydroxyvitamin D [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/104\">",
"     104",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38184?source=see_link&amp;anchor=H4#H4\">",
"     \"Causes of vitamin D deficiency and resistance\", section on 'Elderly'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In older subjects with low serum 25-hydroxyvitamin D concentrations, raising the concentrations to near the middle of the normal range reduces their serum PTH concentrations, supporting the hypothesis that mild vitamin D deficiency is the main cause of their higher serum PTH concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/105,106\">",
"     105,106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prevalent vitamin D deficiency almost certainly contributes to osteoporosis, falls, and fractures in older persons [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/107,108\">",
"     107,108",
"    </a>",
"    ]. It has become apparent that low vitamin D is also associated with important cardiovascular disease risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/109\">",
"     109",
"    </a>",
"    ], declining strength and physical function [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/110\">",
"     110",
"    </a>",
"    ], and risk of certain cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/111,112\">",
"     111,112",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31193?source=see_link\">",
"     \"Vitamin D and extraskeletal health\"",
"    </a>",
"    .) It has been recommended that persons over 70 years old should have a dietary vitamin D intake of at least 600 to 800 int. units daily. In practice this means taking supplemental vitamin D. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of vitamin D deficiency in adults\", section on 'Optimal intake'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Calcium balance",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many older subjects, calcium balance is negative, due to decreased dietary calcium intake as well as decreased fractional absorption of the calcium that is taken in. The recommended intake for men and women over age 65 years is 1200 mg of elemental calcium daily. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=see_link&amp;anchor=H2#H2\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\", section on 'Efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The acceptable &ldquo;normal&rdquo; level of vitamin D remains controversial but surveys have shown that low serum vitamin D is more common with increasing age, especially at higher latitudes, and that low vitamin D levels may be associated not only with more fractures but increased incidence of other chronic diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/113\">",
"     113",
"    </a>",
"    ]. Finally, as noted above, calcium loss is accelerated in elderly persons with hyponatremia. The topic of vitamin D deficiency and supplementation in the elderly is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=see_link&amp;anchor=H5541302#H5541302\">",
"     \"Treatment of vitamin D deficiency in adults\", section on 'Groups at high risk for suboptimal intake'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     CHANGES IN FUEL REGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several age-related changes in the regulation of glucose metabolism and appetite.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Insulin regulation of glucose metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older subjects are less sensitive to insulin than younger subjects, as evidenced by hyperinsulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/114\">",
"     114",
"    </a>",
"    ], a small decrease in glucose tolerance, and a 50 percent reduction in insulin sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/115\">",
"     115",
"    </a>",
"    ]. These changes persist even when the data are corrected for fat mass and fitness, two determinants of glucose disposal [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/116\">",
"     116",
"    </a>",
"    ]. The insulin resistance is at least partly related to a decrease in the muscle content of the glucose carrier protein, GLUT 4 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A decrease in insulin secretion may also contribute to the lower glucose tolerance in older subjects, in addition to decreased insulin sensitivity. Not all older subjects have hyperinsulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/115,118\">",
"     115,118",
"    </a>",
"    ], some of them have hyperproinsulinemia rather than hyperinsulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/119\">",
"     119",
"    </a>",
"    ], and in some older subjects the serum insulin responses to glucose ingestion are sluggish [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On balance, the decrease in glucose clearance with age is mainly related to a decrease in tissue responsiveness to insulin with a lesser contribution from a slight impairment in insulin secretion. These changes are similar to those that typically precede the development of type 2 diabetes mellitus in middle age, and in fact the incidence of type 2 diabetes is higher in older that younger adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/33/14874?source=see_link\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Leptin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leptin, a hormone produced by adipose tissue in proportion to body fat mass, decreases appetite. Serum leptin concentrations decrease with increasing age [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/120\">",
"     120",
"    </a>",
"    ], although some find this to be so only in women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/121\">",
"     121",
"    </a>",
"    ]. The modest fall in serum leptin concentrations with age may contribute to increasing adiposity in older persons.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Adiponectin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adiponectin is a recently described protein hormone secreted by adipocytes. It reduces insulin resistance, is associated with lower risk of atherosclerosis, and has anti-inflammatory properties. Higher levels of adiponectin are associated with lower risk of diabetes in older men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/122\">",
"     122",
"    </a>",
"    ], but the extent to which this hormone is a marker of reduced abdominal visceral fat content or a mediator of insulin sensitivity when visceral fat is depleted is as yet unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=see_link&amp;anchor=H22#H22\">",
"     \"Pathogenesis of type 2 diabetes mellitus\", section on 'Adiponectin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study of 58 women and 67 men, ages 20 to 93 years analyzed by age group (&lt;50, 50 to 70, and &gt;70 years), plasma adiponectin concentrations did not change significantly with age in women, but were higher in men over age 70 compared with younger men [",
"    <a class=\"abstract\" href=\"UTD.htm?12/22/12650/abstract/123\">",
"     123",
"    </a>",
"    ]. The higher levels of adiponectin observed in older men could reflect a longitudinal aging change or simply enhanced survival of men with more of this adipokine. Further studies will be required to elucidate this question.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/26/17826?source=see_link\">",
"       \"Patient information: Growth hormone treatment (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;When considering changes in endocrine function in older people, it is important to distinguish between the effects of aging per se on endocrine physiology and those caused by age-related illness, given the high prevalence of disorders, both symptomatic and asymptomatic, in the elderly. In addition, the distinction between age- and disease-related changes does not necessarily determine therapeutic intervention. The endocrine changes of aging are summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The only endocrine system for which there is a well-defined, abrupt, and universal change in function with age is the hypothalamic-pituitary-gonadal axis in women (ie, menopause).",
"     </li>",
"     <li>",
"      The function of the growth hormone-insulin-like growth factor 1 (IGF-1) system, the male hypothalamic-pituitary-gonadal axis, and the portion (zona reticularis) of the adrenal cortex that synthesizes DHEA all decline progressively with age in most people. Age-adjusted ranges of normal values for serum IGF-1, total and free or bioavailable testosterone, and DHEA concentrations can be defined, but whether these values are physiologically optimal is unknown.",
"     </li>",
"     <li>",
"      The secretion of some other hormones is also altered with age, but changes are much less predictable, and there are no well-defined, age-adjusted normal values.",
"     </li>",
"     <li>",
"      The action of some hormones decreases with age; increased hormonal secretion may or may not compensate for such decreases in tissue responsiveness.",
"     </li>",
"     <li>",
"      The case for routine replacement therapy with growth hormone, sex steroids, or other hormones in the elderly remains controversial but, as a generality, the use of such therapy is not supported by the majority of studies to date, and may have unanticipated adverse consequences. That said, the diagnosis and treatment of true hormone deficiency diseases in the elderly (such as subclinical hypothyroidism) remains a challenge and chronic endocrine-related conditions such as &ldquo;benign&rdquo; hyponatremia deserve attention and may require treatment.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/1\">",
"      Bokov A, Chaudhuri A, Richardson A. The role of oxidative damage and stress in aging. Mech Ageing Dev 2004; 125:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/2\">",
"      Suji G, Sivakami S. Glucose, glycation and aging. Biogerontology 2004; 5:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/3\">",
"      Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/4\">",
"      Conboy IM, Conboy MJ, Wagers AJ, et al. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature 2005; 433:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/5\">",
"      Villeda SA, Luo J, Mosher KI, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 2011; 477:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/6\">",
"      Post WS, Goldschmidt-Clermont PJ, Wilhide CC, et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res 1999; 43:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/7\">",
"      Harman SM, Tsitouras PD. Reproductive hormones in aging men. I. Measurement of sex steroids, basal luteinizing hormone, and Leydig cell response to human chorionic gonadotropin. J Clin Endocrinol Metab 1980; 51:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/8\">",
"      Mulligan T, Iranmanesh A, Kerzner R, et al. Two-week pulsatile gonadotropin releasing hormone infusion unmasks dual (hypothalamic and Leydig cell) defects in the healthy aging male gonadotropic axis. Eur J Endocrinol 1999; 141:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/9\">",
"      van Coevorden A, Mockel J, Laurent E, et al. Neuroendocrine rhythms and sleep in aging men. Am J Physiol 1991; 260:E651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/10\">",
"      Florini JR, Prinz PN, Vitiello MV, Hintz RL. Somatomedin-C levels in healthy young and old men: relationship to peak and 24-hour integrated levels of growth hormone. J Gerontol 1985; 40:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/11\">",
"      Pavlov EP, Harman SM, Merriam GR, et al. Responses of growth hormone (GH) and somatomedin-C to GH-releasing hormone in healthy aging men. J Clin Endocrinol Metab 1986; 62:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/12\">",
"      Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev 1993; 14:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/13\">",
"      Iovino M, Monteleone P, Steardo L. Repetitive growth hormone-releasing hormone administration restores the attenuated growth hormone (GH) response to GH-releasing hormone testing in normal aging. J Clin Endocrinol Metab 1989; 69:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/14\">",
"      Russell-Aulet M, Jaffe CA, Demott-Friberg R, Barkan AL. In vivo semiquantification of hypothalamic growth hormone-releasing hormone (GHRH) output in humans: evidence for relative GHRH deficiency in aging. J Clin Endocrinol Metab 1999; 84:3490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/15\">",
"      Vahl N, J&oslash;rgensen JO, Jurik AG, Christiansen JS. Abdominal adiposity and physical fitness are major determinants of the age associated decline in stimulated GH secretion in healthy adults. J Clin Endocrinol Metab 1996; 81:2209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/16\">",
"      Van Cauter E, Plat L, Scharf MB, et al. Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxybutyrate in normal young Men. J Clin Invest 1997; 100:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/17\">",
"      Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990; 323:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/18\">",
"      Blackman MR, Sorkin JD, M&uuml;nzer T, et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA 2002; 288:2282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/19\">",
"      Yarasheski KE, Zachwieja JJ, Campbell JA, Bier DM. Effect of growth hormone and resistance exercise on muscle growth and strength in older men. Am J Physiol 1995; 268:E268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/20\">",
"      Taaffe DR, Jin IH, Vu TH, et al. Lack of effect of recombinant human growth hormone (GH) on muscle morphology and GH-insulin-like growth factor expression in resistance-trained elderly men. J Clin Endocrinol Metab 1996; 81:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/21\">",
"      Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab 1997; 82:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/22\">",
"      Huang X, Blackman MR, Herreman K, et al. Effects of growth hormone and/or sex steroid administration on whole-body protein turnover in healthy aged women and men. Metabolism 2005; 54:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/23\">",
"      Welle S, Thornton C, Statt M, McHenry B. Growth hormone increases muscle mass and strength but does not rejuvenate myofibrillar protein synthesis in healthy subjects over 60 years old. J Clin Endocrinol Metab 1996; 81:3239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/24\">",
"      White HK, Petrie CD, Landschulz W, et al. Effects of an oral growth hormone secretagogue in older adults. J Clin Endocrinol Metab 2009; 94:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/25\">",
"      Attanasio AF, Bates PC, Ho KK, et al. Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status--3-year results from the HypoCCS Database. J Clin Endocrinol Metab 2002; 87:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/26\">",
"      Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 2007; 146:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/27\">",
"      Bartke A, Brown-Borg H. Life extension in the dwarf mouse. Curr Top Dev Biol 2004; 63:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/28\">",
"      Coschigano KT, Clemmons D, Bellush LL, Kopchick JJ. Assessment of growth parameters and life span of GHR/BP gene-disrupted mice. Endocrinology 2000; 141:2608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/29\">",
"      Helderman JH, Vestal RE, Rowe JW, et al. The response of arginine vasopressin to intravenous ethanol and hypertonic saline in man: the impact of aging. J Gerontol 1978; 33:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/30\">",
"      Stachenfeld NS, Mack GW, Takamata A, et al. Thirst and fluid regulatory responses to hypertonicity in older adults. Am J Physiol 1996; 271:R757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/31\">",
"      Phillips PA, Rolls BJ, Ledingham JG, et al. Reduced thirst after water deprivation in healthy elderly men. N Engl J Med 1984; 311:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/32\">",
"      Weinberg AD, Minaker KL. Dehydration. Evaluation and management in older adults. Council on Scientific Affairs, American Medical Association. JAMA 1995; 274:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/33\">",
"      Miller M, Hecker MS, Friedlander DA, Carter JM. Apparent idiopathic hyponatremia in an ambulatory geriatric population. J Am Geriatr Soc 1996; 44:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/34\">",
"      Crowe MJ, Forsling ML, Rolls BJ, et al. Altered water excretion in healthy elderly men. Age Ageing 1987; 16:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/35\">",
"      Saito T, Fukagawa A, Higashiyama M, et al. Close association of urinary excretion of aquaporin-2 with appropriate and inappropriate arginine vasopressin-dependent antidiuresis in hyponatremia in elderly subjects. J Clin Endocrinol Metab 2001; 86:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/36\">",
"      Verbalis JG, Barsony J, Sugimura Y, et al. Hyponatremia-induced osteoporosis. J Bone Miner Res 2010; 25:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/37\">",
"      Barsony J, Sugimura Y, Verbalis JG. Osteoclast response to low extracellular sodium and the mechanism of hyponatremia-induced bone loss. J Biol Chem 2011; 286:10864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/38\">",
"      Garfinkel D, Laudon M, Nof D, Zisapel N. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet 1995; 346:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/39\">",
"      Wurtman RJ. Age-related decreases in melatonin secretion--clinical consequences. J Clin Endocrinol Metab 2000; 85:2135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/40\">",
"      Parker CR Jr, Slayden SM, Azziz R, et al. Effects of aging on adrenal function in the human: responsiveness and sensitivity of adrenal androgens and cortisol to adrenocorticotropin in premenopausal and postmenopausal women. J Clin Endocrinol Metab 2000; 85:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/41\">",
"      Waltman C, Blackman MR, Chrousos GP, et al. Spontaneous and glucocorticoid-inhibited adrenocorticotropic hormone and cortisol secretion are similar in healthy young and old men. J Clin Endocrinol Metab 1991; 73:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/42\">",
"      Bergendahl M, Iranmanesh A, Mulligan T, Veldhuis JD. Impact of age on cortisol secretory dynamics basally and as driven by nutrient-withdrawal stress. J Clin Endocrinol Metab 2000; 85:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/43\">",
"      Van Cauter E, Leproult R, Kupfer DJ. Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol. J Clin Endocrinol Metab 1996; 81:2468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/44\">",
"      Sherman B, Wysham C, Pfohl B. Age-related changes in the circadian rhythm of plasma cortisol in man. J Clin Endocrinol Metab 1985; 61:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/45\">",
"      Seeman TE, Robbins RJ. Aging and hypothalamic-pituitary-adrenal response to challenge in humans. Endocr Rev 1994; 15:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/46\">",
"      Seeman TE, McEwen BS, Singer BH, et al. Increase in urinary cortisol excretion and memory declines: MacArthur studies of successful aging. J Clin Endocrinol Metab 1997; 82:2458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/47\">",
"      Dennison E, Hindmarsh P, Fall C, et al. Profiles of endogenous circulating cortisol and bone mineral density in healthy elderly men. J Clin Endocrinol Metab 1999; 84:3058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/48\">",
"      Greendale GA, Unger JB, Rowe JW, Seeman TE. The relation between cortisol excretion and fractures in healthy older people: results from the MacArthur studies-Mac. J Am Geriatr Soc 1999; 47:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/49\">",
"      Purnell JQ, Brandon DD, Isabelle LM, et al. Association of 24-hour cortisol production rates, cortisol-binding globulin, and plasma-free cortisol levels with body composition, leptin levels, and aging in adult men and women. J Clin Endocrinol Metab 2004; 89:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/50\">",
"      Flood C, Gherondache C, Pincus G, et al. The metabolism and secretion of aldosterone in elderly subjects. J Clin Invest 1967; 46:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/51\">",
"      Bauer JH. Age-related changes in the renin-aldosterone system. Physiological effects and clinical implications. Drugs Aging 1993; 3:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/52\">",
"      Davis KM, Fish LC, Minaker KL, Elahi D. Atrial natriuretic peptide levels in the elderly: differentiating normal aging changes from disease. J Gerontol A Biol Sci Med Sci 1996; 51:M95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/53\">",
"      Barrou Z, Charru P, Lidy C. [Actions of dehydroepiandrosterone: possible links with aging]. Presse Med 1996; 25:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/54\">",
"      Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci U S A 2000; 97:4279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/55\">",
"      Davison SL, Bell R, Donath S, et al. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005; 90:3847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/56\">",
"      Leng SX, Cappola AR, Andersen RE, et al. Serum levels of insulin-like growth factor-I (IGF-I) and dehydroepiandrosterone sulfate (DHEA-S), and their relationships with serum interleukin-6, in the geriatric syndrome of frailty. Aging Clin Exp Res 2004; 16:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/57\">",
"      Nair KS, Rizza RA, O'Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006; 355:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/58\">",
"      Morrow LA, Linares OA, Hill TJ, et al. Age differences in the plasma clearance mechanisms for epinephrine and norepinephrine in humans. J Clin Endocrinol Metab 1987; 65:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/59\">",
"      Esler M, Kaye D, Thompson J, et al. Effects of aging on epinephrine secretion and regional release of epinephrine from the human heart. J Clin Endocrinol Metab 1995; 80:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/60\">",
"      Prinz PN, Vitiello MV, Smallwood RG, et al. Plasma norepinephrine in normal young and aged men: relationship with sleep. J Gerontol 1984; 39:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/61\">",
"      Schwartz RS, Jaeger LF, Veith RC. The importance of body composition to the increase in plasma norepinephrine appearance rate in elderly men. J Gerontol 1987; 42:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/62\">",
"      Morrow LA, Rosen SG, Halter JB. Beta-adrenergic regulation of insulin secretion: evidence of tissue heterogeneity of beta-adrenergic responsiveness in the elderly. J Gerontol 1991; 46:M108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/63\">",
"      Hogikyan RV, Supiano MA. Arterial alpha-adrenergic responsiveness is decreased and SNS activity is increased in older humans. Am J Physiol 1994; 266:E717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/64\">",
"      Heged&uuml;s L. Thyroid size determined by ultrasound. Influence of physiological factors and non-thyroidal disease. Dan Med Bull 1990; 37:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/65\">",
"      Braverman LW, Dawber NA, Ingbar SH. Observations concerning the binding of thyroid hormones in sera of normal subjects of varying ages. J Clin Invest 1966; 45:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/66\">",
"      Blum CJ, Lafont C, Ducasse M, et al. Thyroid function tests in ageing and their relation to associated nonthyroidal disease. J Endocrinol Invest 1989; 12:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/67\">",
"      Runnels BL, Garry PJ, Hunt WC, Standefer JC. Thyroid function in a healthy elderly population: implications for clinical evaluation. J Gerontol 1991; 46:B39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/68\">",
"      P&eacute;nzes, L, Gergely, I. Thyroid hormones in the light of general health status of Hungarian centenarians. Age 1989; 12:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/69\">",
"      Franklyn JA, Ramsden DB, Sheppard MC. The influence of age and sex on tests of thyroid function. Ann Clin Biochem 1985; 22 ( Pt 5):502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/70\">",
"      Oddie TH, Meade JH Jr, Fisher DA. An analysis of published data on thyroxine turnover in human subjects. J Clin Endocrinol Metab 1966; 26:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/71\">",
"      Olsen T, Laurberg P, Weeke J. Low serum triiodothyronine and high serum reverse triiodothyronine in old age: an effect of disease not age. J Clin Endocrinol Metab 1978; 47:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/72\">",
"      Mariotti S, Barbesino G, Caturegli P, et al. Complex alteration of thyroid function in healthy centenarians. J Clin Endocrinol Metab 1993; 77:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/73\">",
"      Magri F, Muzzoni B, Cravello L, et al. Thyroid function in physiological aging and in centenarians: possible relationships with some nutritional markers. Metabolism 2002; 51:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/74\">",
"      GAFFNEY GW, GREGERMAN RI, SHOCK NW. Relationship of age to the thyroidal accumulation, renal excretion and distribution of radioiodide in euthyroid man. J Clin Endocrinol Metab 1962; 22:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/75\">",
"      Tunbridge WM, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) 1977; 7:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/76\">",
"      Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995; 43:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/77\">",
"      Sawin CT, Geller A, Kaplan MM, et al. Low serum thyrotropin (thyroid-stimulating hormone) in older persons without hyperthyroidism. Arch Intern Med 1991; 151:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/78\">",
"      Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med 2000; 160:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/79\">",
"      Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/80\">",
"      Greenspan SL, Klibanski A, Rowe JW, Elahi D. Age-related alterations in pulsatile secretion of TSH: role of dopaminergic regulation. Am J Physiol 1991; 260:E486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/81\">",
"      Stott DJ, McLellan AR, Finlayson J, et al. Elderly patients with suppressed serum TSH but normal free thyroid hormone levels usually have mild thyroid overactivity and are at increased risk of developing overt hyperthyroidism. Q J Med 1991; 78:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/82\">",
"      Bjoro T, Holmen J, Kr&uuml;ger O, et al. Prevalence of thyroid disease, thyroid dysfunction and thyroid peroxidase antibodies in a large, unselected population. The Health Study of Nord-Trondelag (HUNT). Eur J Endocrinol 2000; 143:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/83\">",
"      Chiovato L, Mariotti S, Pinchera A. Thyroid diseases in the elderly. Baillieres Clin Endocrinol Metab 1997; 11:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/84\">",
"      Frost L, Vestergaard P, Mosekilde L. Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study. Arch Intern Med 2004; 164:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/85\">",
"      Schindler AE. Thyroid function and postmenopause. Gynecol Endocrinol 2003; 17:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/86\">",
"      Volpato S, Guralnik JM, Fried LP, et al. Serum thyroxine level and cognitive decline in euthyroid older women. Neurology 2002; 58:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/87\">",
"      Chueire VB, Romaldini JH, Ward LS. Subclinical hypothyroidism increases the risk for depression in the elderly. Arch Gerontol Geriatr 2007; 44:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/88\">",
"      Roberts LM, Pattison H, Roalfe A, et al. Is subclinical thyroid dysfunction in the elderly associated with depression or cognitive dysfunction? Ann Intern Med 2006; 145:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/89\">",
"      Razvi S, Ingoe L, Keeka G, et al. The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. J Clin Endocrinol Metab 2007; 92:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/90\">",
"      Gussekloo J, van Exel E, de Craen AJ, et al. Thyroid status, disability and cognitive function, and survival in old age. JAMA 2004; 292:2591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/91\">",
"      Vaninetti S, Baccarelli A, Romoli R, et al. Effect of aging on serum gonadotropin levels in healthy subjects and patients with nonfunctioning pituitary adenomas. Eur J Endocrinol 2000; 142:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/92\">",
"      Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/93\">",
"      Saad F, Gooren LJ, Haider A, Yassin A. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl 2008; 29:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/94\">",
"      Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008; 93:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/95\">",
"      Shores MM, Smith NL, Forsberg CW, et al. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 2012; 97:2050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/96\">",
"      Moffat SD, Zonderman AB, Metter EJ, et al. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab 2002; 87:5001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/97\">",
"      Hogervorst E, Bandelow S, Combrinck M, Smith AD. Low free testosterone is an independent risk factor for Alzheimer's disease. Exp Gerontol 2004; 39:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/98\">",
"      Chu LW, Tam S, Lee PW, et al. Bioavailable testosterone is associated with a reduced risk of amnestic mild cognitive impairment in older men. Clin Endocrinol (Oxf) 2008; 68:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/99\">",
"      Burkhardt MS, Foster JK, Clarnette RM, et al. Interaction between testosterone and apolipoprotein E epsilon4 status on cognition in healthy older men. J Clin Endocrinol Metab 2006; 91:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/100\">",
"      Kenny AM, Bellantonio S, Gruman CA, et al. Effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2002; 57:M321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/101\">",
"      Maki PM, Ernst M, London ED, et al. Intramuscular testosterone treatment in elderly men: evidence of memory decline and altered brain function. J Clin Endocrinol Metab 2007; 92:4107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/102\">",
"      Sherman SS, Hollis BW, Tobin JD. Vitamin D status and related parameters in a healthy population: the effects of age, sex, and season. J Clin Endocrinol Metab 1990; 71:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/103\">",
"      MacLaughlin J, Holick MF. Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest 1985; 76:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/104\">",
"      Pattanaungkul S, Riggs BL, Yergey AL, et al. Relationship of intestinal calcium absorption to 1,25-dihydroxyvitamin D [1,25(OH)2D] levels in young versus elderly women: evidence for age-related intestinal resistance to 1,25(OH)2D action. J Clin Endocrinol Metab 2000; 85:4023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/105\">",
"      Lips P, Wiersinga A, van Ginkel FC, et al. The effect of vitamin D supplementation on vitamin D status and parathyroid function in elderly subjects. J Clin Endocrinol Metab 1988; 67:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/106\">",
"      Ledger GA, Burritt MF, Kao PC, et al. Abnormalities of parathyroid hormone secretion in elderly women that are reversible by short term therapy with 1,25-dihydroxyvitamin D3. J Clin Endocrinol Metab 1994; 79:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/107\">",
"      Stein MS, Wark JD, Scherer SC, et al. Falls relate to vitamin D and parathyroid hormone in an Australian nursing home and hostel. J Am Geriatr Soc 1999; 47:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/108\">",
"      Villareal DT, Civitelli R, Chines A, Avioli LV. Subclinical vitamin D deficiency in postmenopausal women with low vertebral bone mass. J Clin Endocrinol Metab 1991; 72:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/109\">",
"      Martins D, Wolf M, Pan D, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2007; 167:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/110\">",
"      Wicherts IS, van Schoor NM, Boeke AJ, et al. Vitamin D status predicts physical performance and its decline in older persons. J Clin Endocrinol Metab 2007; 92:2058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/111\">",
"      Knight JA, Lesosky M, Barnett H, et al. Vitamin D and reduced risk of breast cancer: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007; 16:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/112\">",
"      Giovannucci E, Liu Y, Willett WC. Cancer incidence and mortality and vitamin D in black and white male health professionals. Cancer Epidemiol Biomarkers Prev 2006; 15:2467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/113\">",
"      Mosekilde L. Vitamin D and the elderly. Clin Endocrinol (Oxf) 2005; 62:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/114\">",
"      Gumbiner B, Polonsky KS, Beltz WF, et al. Effects of aging on insulin secretion. Diabetes 1989; 38:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/115\">",
"      R&oslash;der ME, Schwartz RS, Prigeon RL, Kahn SE. Reduced pancreatic B cell compensation to the insulin resistance of aging: impact on proinsulin and insulin levels. J Clin Endocrinol Metab 2000; 85:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/116\">",
"      Shimokata H, Muller DC, Fleg JL, et al. Age as independent determinant of glucose tolerance. Diabetes 1991; 40:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/117\">",
"      Houmard JA, Weidner MD, Dolan PL, et al. Skeletal muscle GLUT4 protein concentration and aging in humans. Diabetes 1995; 44:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/118\">",
"      Chen M, Bergman RN, Pacini G, Porte D Jr. Pathogenesis of age-related glucose intolerance in man: insulin resistance and decreased beta-cell function. J Clin Endocrinol Metab 1985; 60:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/119\">",
"      Gama R, Medina-Layachi N, Ranganath L, et al. Hyperproinsulinaemia in elderly subjects: evidence for age-related pancreatic beta-cell dysfunction. Ann Clin Biochem 2000; 37 ( Pt 3):367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/120\">",
"      Isidori AM, Strollo F, Mor&egrave; M, et al. Leptin and aging: correlation with endocrine changes in male and female healthy adult populations of different body weights. J Clin Endocrinol Metab 2000; 85:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/121\">",
"      Neuh&auml;user-Berthold M, Herbert BM, L&uuml;hrmann PM, et al. Resting metabolic rate, body composition, and serum leptin concentrations in a free-living elderly population. Eur J Endocrinol 2000; 142:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/122\">",
"      Kanaya AM, Harris T, Goodpaster BH, et al. Adipocytokines attenuate the association between visceral adiposity and diabetes in older adults. Diabetes Care 2004; 27:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/22/12650/abstract/123\">",
"      Adamczak M, Rzepka E, Chudek J, Wiecek A. Ageing and plasma adiponectin concentration in apparently healthy males and females. Clin Endocrinol (Oxf) 2005; 62:114.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3006 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-5849588C53-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_22_12650=[""].join("\n");
var outline_f12_22_12650=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHYSIOLOGY OF AGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Endocrine changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HYPOTHALAMIC-PITUITARY FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Changes in growth hormone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Growth hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      VASOPRESSIN AND WATER BALANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PINEAL FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ADRENOCORTICAL FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cortisol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Aldosterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dehydroepiandrosterone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ADRENOMEDULLARY FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PITUITARY-THYROID FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Thyrotropin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H528468\">",
"      Thyroid disease in the elderly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PITUITARY-GONADAL FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CALCIOTROPIC HORMONE PRODUCTION AND CALCIUM BALANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Parathyroid hormone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Vitamin D",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Calcium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      CHANGES IN FUEL REGULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Insulin regulation of glucose metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Leptin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Adiponectin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38184?source=related_link\">",
"      Causes of vitamin D deficiency and resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/33/14874?source=related_link\">",
"      Classification of diabetes mellitus and genetic diabetic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44761?source=related_link\">",
"      Clinical manifestations and diagnosis of menopause",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/16/263?source=related_link\">",
"      Dehydroepiandrosterone and its sulfate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=related_link\">",
"      Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1833?source=related_link\">",
"      Growth hormone deficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/3/31800?source=related_link\">",
"      Male reproductive physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15720?source=related_link\">",
"      Ovarian development and failure (menopause) in normal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4314?source=related_link\">",
"      Overview of testosterone deficiency in elderly men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=related_link\">",
"      Overview of the clinical manifestations of hyperthyroidism in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=related_link\">",
"      Pathogenesis of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/26/17826?source=related_link\">",
"      Patient information: Growth hormone treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13034?source=related_link\">",
"      Physiology and clinical use of melatonin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43030?source=related_link\">",
"      Physiology of growth hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/7/3192?source=related_link\">",
"      Physiology of insulin-like growth factor I",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3850?source=related_link\">",
"      Subclinical hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=related_link\">",
"      Treatment of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31193?source=related_link\">",
"      Vitamin D and extraskeletal health",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_22_12651="Triggers autonomic dysreflexia";
var content_f12_22_12651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Triggers of autonomic dysreflexia in pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         Pelvis:",
"        </strong>",
"        manipulation of the vagina or cervix, bimanual examination, insertion of a vaginal speculum, swabbing the cervix or posterior fornix, or uterine contractions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Genitourinary:",
"        </strong>",
"        manipulation of urinary catheters, catheter insertion, catheter obstruction, vesico-ureteral reflux, or renal colic.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Gastrointestinal:",
"        </strong>",
"        constipation, biliary colic, various gastrointestinal pathologies.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Dermatologic:",
"        </strong>",
"        decubitus ulcers, temperature variation below the level of the spinal cord lesion such as immersion of feet in cold or hot water, or placement of feet in cold stirrups.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Other:",
"        </strong>",
"        sexual activity",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Pereira, L. Obstet Gynecol Surv 2003; 58:678.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_22_12651=[""].join("\n");
var outline_f12_22_12651=null;
var title_f12_22_12652="Activity energy child";
var content_f12_22_12652=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Age-adjusted metabolic equivalents of adolescent boys and girls as multiples of resting metabolic rate",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Activity",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Age-adjusted metabolic equivalents (MET)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Ages: 13-15 years for boys and 12-14 years for girls",
"       </td>",
"       <td class=\"subtitle2\">",
"        Ages: 16-18 years for boys and 15-18 years for girls",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Homework/reading",
"       </td>",
"       <td>",
"        1.17",
"       </td>",
"       <td>",
"        1.13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TV watching",
"       </td>",
"       <td>",
"        1.06",
"       </td>",
"       <td>",
"        1.02",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Video game sitting",
"       </td>",
"       <td>",
"        1.28",
"       </td>",
"       <td>",
"        1.26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Video game standing",
"       </td>",
"       <td>",
"        1.47",
"       </td>",
"       <td>",
"        1.47",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sweeping",
"       </td>",
"       <td>",
"        3.12",
"       </td>",
"       <td>",
"        2.83",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Walking 2.5 mph",
"       </td>",
"       <td>",
"        3.49",
"       </td>",
"       <td>",
"        3.32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vacuuming",
"       </td>",
"       <td>",
"        3.81",
"       </td>",
"       <td>",
"        3.37",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Walking 3.5 mph",
"       </td>",
"       <td>",
"        4.66",
"       </td>",
"       <td>",
"        4.52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stair climbing",
"       </td>",
"       <td>",
"        6.51",
"       </td>",
"       <td>",
"        6.51",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rope skipping",
"       </td>",
"       <td>",
"        8.04",
"       </td>",
"       <td>",
"        7.52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Running 5 mph",
"       </td>",
"       <td>",
"        8.25",
"       </td>",
"       <td>",
"        8.13",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Age-adjusted metabolic equivalent (MET) = VO",
"     <sub>",
"      2",
"     </sub>",
"     of activity/VO",
"     <sub>",
"      2",
"     </sub>",
"     at rest.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Harrell, JS, McMurray, RG, Baggett, CD, et al. Energy costs of physical activities in children and adolescents. Med Sci Sports Exerc 2005; 37:329.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_22_12652=[""].join("\n");
var outline_f12_22_12652=null;
var title_f12_22_12653="Vitamins PN preterm infant";
var content_f12_22_12653=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76606&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76606&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested intakes of vitamins for premature infants receiving parenteral nutrition",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Vitamin",
"       </td>",
"       <td class=\"subtitle1\">",
"        Current regimen based upon pediatric multivitamin formulation* (unit/kg/day)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Estimate based upon the needs of premature infants (unit/kg/day)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Maximum not to exceed term infant (unit/day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Fat-soluble vitamins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A (microg)&bull;",
"       </td>",
"       <td>",
"        280",
"       </td>",
"       <td>",
"        500",
"       </td>",
"       <td>",
"        700",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        E (mg)&Delta;",
"       </td>",
"       <td>",
"        2.8",
"       </td>",
"       <td>",
"        2.8",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        K (microg)",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        200",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        D (microg)&loz;",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Water-soluble vitamins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        C, Ascorbic acid (mg)",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        B1, Thiamin (mg)",
"       </td>",
"       <td>",
"        0.48",
"       </td>",
"       <td>",
"        0.35",
"       </td>",
"       <td>",
"        1.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        B2, Riboflavin (mg)",
"       </td>",
"       <td>",
"        0.56",
"       </td>",
"       <td>",
"        0.15",
"       </td>",
"       <td>",
"        1.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        B6, Pyridoxine (mg)",
"       </td>",
"       <td>",
"        0.40",
"       </td>",
"       <td>",
"        0.18",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Niacin (mg)",
"       </td>",
"       <td>",
"        6.8",
"       </td>",
"       <td>",
"        6.8",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pantothenate (mg)",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Biotin (microg)",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Folate (microg)",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        140",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin B12 (microg)",
"       </td>",
"       <td>",
"        0.40",
"       </td>",
"       <td>",
"        0.30",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Regimen based upon using 40 percent of a vial of MVI-Pediatric (Mayne Pharma (USA), Inc., Paramus, NJ) per kg body weight or 2 mL/kg/day. Infuvite Pediatric (Sandoz Canada Inc., Boucherville, Quebec, Canada) has composition similar to MVI-Pediatric, with the following exceptions (per 5 mL): aluminum (4.2 versus 0.2 microg) and polysorbate 20 (0 versus 0.8 mg), in Infuvite versus MVI-Pediatric, respectively.",
"     <br>",
"      &bull; 1 microg retinol = 3.33&nbsp;int. unit&nbsp;vitamin A = 6 microg",
"      <sub>",
"       &beta;",
"      </sub>",
"      -carotene = 1.83 microg retinyl palmitate = 1 retinol equivalent (RE).",
"      <br>",
"       &Delta; 1 mg &alpha;-tocopherol = 1&nbsp;int. unit&nbsp;vitamin E.",
"       <br>",
"        &loz; 1 microg vitamin D (cholecalciferol) = 40&nbsp;int. unit&nbsp;vitamin D (cholecalciferol).",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <br>",
"      1. Schanler RJ. The low birth weight infant: Perinatal nutrition. In: Nutrition in Pediatrics: Basic Science and Clinical Applications, Walker WA, Watkins JB (Eds), B.C. Decker Inc., Hamilton, Ontario, Canada 1996. p.387.",
"      <br>",
"       2. Greene HL, Hambidge KM, Schanler RJ, Tsang RC. Guidelines for the use of vitamins, trace elements, calcium, magnesium, and phosphorus in infants and children receiving total parenteral nutrition: report of the Subcommittee on Pediatric Parenteral Nutrient Requirements from the Committee on Clinical Practice Issues of The American Society for Clinical Nutrition. Am J Clin Nutr 1988; 48:1324.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_22_12653=[""].join("\n");
var outline_f12_22_12653=null;
var title_f12_22_12654="Diagnosis of HIV by sex and age";
var content_f12_22_12654=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Diagnoses of HIV infection among adolescents and adults by sex and age group, 2010 - 46 states and 5 US-dependent areas",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 376px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. Data from&nbsp;46 states and 5 US-dependent areas with confidential name-based HIV infection reporting since at least January 2007. All displayed data have been statistically adjusted to account for reporting delays, but not for incomplete reporting.",
"    <div class=\"footnotes\">",
"     HIV: human immunodeficiency virus.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. HIV surveillance in adolescents and young adults. Available at:&nbsp;",
"     <a href=\"file://www.cdc.gov/hiv/topics/surveillance/resources/slides/adolescents/index.htm\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"      file://www.cdc.gov/hiv/topics/surveillance/resources/slides/adolescents/index.htm",
"     </a>",
"     (Accessed on August 20, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_22_12654=[""].join("\n");
var outline_f12_22_12654=null;
var title_f12_22_12655="Rel risk disease BMI";
var content_f12_22_12655=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F76866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F76866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Body-mass index and the risk of disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 449px; height: 600px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Increasing body-mass index (BMI kg/m2), even within the normal range of BMI (21 to 24.9), is associated with an increased risk of type 2 diabetes, hypertension, coronary heart disease, and cholelithiasis. Panel A shows data for women in the Nurses' Health Study, initially 30 to 55 years of age, who were followed for up to 18 years. Panel B shows data for men in the Health Professionals Follow-up Study, initially 40 to 65 years of age, who were followed for up to 10 years.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999; 341:427.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_22_12655=[""].join("\n");
var outline_f12_22_12655=null;
